YU44066B - Process for preparing a new poly (lactid-co-glycolyd)-polymer - Google Patents

Process for preparing a new poly (lactid-co-glycolyd)-polymer

Info

Publication number
YU44066B
YU44066B YU315/82A YU31582A YU44066B YU 44066 B YU44066 B YU 44066B YU 315/82 A YU315/82 A YU 315/82A YU 31582 A YU31582 A YU 31582A YU 44066 B YU44066 B YU 44066B
Authority
YU
Yugoslavia
Prior art keywords
glycolyd
lactid
preparing
polymer
new poly
Prior art date
Application number
YU315/82A
Other languages
English (en)
Other versions
YU31582A (en
Inventor
F G Hutchinson
Original Assignee
Ici Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10519727&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=YU44066(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ici Plc filed Critical Ici Plc
Publication of YU31582A publication Critical patent/YU31582A/xx
Publication of YU44066B publication Critical patent/YU44066B/xx
Priority to BA970175A priority Critical patent/BA97175B1/bs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/12—1,4-Dioxanes; Hydrogenated 1,4-dioxanes not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
    • C08G63/06—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from hydroxycarboxylic acids
    • C08G63/08—Lactones or lactides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/28—Bound to a nonpeptide drug, nonpeptide label, nonpeptide carrier, or a nonpeptide resin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Polyethers (AREA)
  • Biological Depolymerization Polymers (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
YU315/82A 1981-02-16 1982-02-15 Process for preparing a new poly (lactid-co-glycolyd)-polymer YU44066B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BA970175A BA97175B1 (bs) 1981-02-16 1997-04-29 Postopek za pripravo novega poli (laktid-ko-glikolid)-polimera

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8104734 1981-02-16

Publications (2)

Publication Number Publication Date
YU31582A YU31582A (en) 1985-04-30
YU44066B true YU44066B (en) 1990-02-28

Family

ID=10519727

Family Applications (1)

Application Number Title Priority Date Filing Date
YU315/82A YU44066B (en) 1981-02-16 1982-02-15 Process for preparing a new poly (lactid-co-glycolyd)-polymer

Country Status (20)

Country Link
US (2) US5004602A (forum.php)
EP (1) EP0058481B2 (forum.php)
JP (4) JPS57150609A (forum.php)
AT (1) ATE22535T1 (forum.php)
AU (3) AU560829B2 (forum.php)
CA (1) CA1169090A (forum.php)
DE (1) DE3273501D1 (forum.php)
DK (1) DK164845B (forum.php)
ES (1) ES8307845A1 (forum.php)
FI (1) FI80594B (forum.php)
GR (1) GR76791B (forum.php)
HK (1) HK107890A (forum.php)
HU (2) HU186904B (forum.php)
IE (1) IE52535B1 (forum.php)
MY (1) MY101545A (forum.php)
NO (1) NO162103C (forum.php)
NZ (1) NZ199732A (forum.php)
PT (1) PT74434B (forum.php)
YU (1) YU44066B (forum.php)
ZA (1) ZA82565B (forum.php)

Families Citing this family (1037)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4637905A (en) * 1982-03-04 1987-01-20 Batelle Development Corporation Process of preparing microcapsules of lactides or lactide copolymers with glycolides and/or ε-caprolactones
FR2537980B1 (fr) * 1982-12-17 1986-12-19 Sandoz Sa Derives d'acides hydroxycarboxyliques oligomeres, leur preparation et leur utilisation
US4652443A (en) * 1983-06-07 1987-03-24 Japan Atomic Energy Research Institute Slow-release composite and process for producing the same
CA1196864A (en) * 1983-06-10 1985-11-19 Mattheus F.A. Goosen Controlled release of injectable and implantable insulin compositions
CH656884A5 (de) * 1983-08-26 1986-07-31 Sandoz Ag Polyolester, deren herstellung und verwendung.
CH661206A5 (fr) * 1983-09-23 1987-07-15 Debiopharm Sa Procede pour la preparation d'un medicament destine au traitement de maladies hormonodependantes.
JPS6097918A (ja) * 1983-11-01 1985-05-31 Sumitomo Chem Co Ltd インタ−フエロン持続性製剤
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
JPS60181029A (ja) * 1984-02-29 1985-09-14 Toyo Jozo Co Ltd 徐放性製剤の製法
GB8416234D0 (en) * 1984-06-26 1984-08-01 Ici Plc Biodegradable amphipathic copolymers
CA1256638A (en) * 1984-07-06 1989-06-27 Motoaki Tanaka Polymer and its production
US4760053A (en) * 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
US4666885A (en) * 1985-02-08 1987-05-19 Fernand Labrie Combination therapy for treatment of female breast cancer
US4880635B1 (en) * 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
DE3434345A1 (de) * 1984-09-19 1986-03-27 Hoechst Ag, 6230 Frankfurt Verwendung von (alpha)-interferonen zur bekaempfung von durchfaellen
DE3678308D1 (de) * 1985-02-07 1991-05-02 Takeda Chemical Industries Ltd Verfahren zur herstellung von mikrokapseln.
FR2581544B1 (fr) * 1985-05-10 1989-11-03 Univ Melbourne Procede pour provoquer une ovulation chez les juments et vehicule pharmaceutique associe
US5169633A (en) * 1985-07-29 1992-12-08 American Cyanamid Company Continuous release phenylethanolamine derivative compositions
US5137874A (en) * 1985-07-29 1992-08-11 American Cyanamid Co. Partially coated C10 -C20 fatty acid salts of peptides having molecular weights up to about 5,000
US5059422A (en) * 1985-07-29 1991-10-22 American Cyanamid Company Continuous release phenylethanolamine derivative compositions
US5102872A (en) * 1985-09-20 1992-04-07 Cetus Corporation Controlled-release formulations of interleukin-2
US4643191A (en) * 1985-11-29 1987-02-17 Ethicon, Inc. Crystalline copolymers of p-dioxanone and lactide and surgical devices made therefrom
JPH0725688B2 (ja) * 1986-03-31 1995-03-22 住友製薬株式会社 Ｃｓｆ徐放性製剤
GB8609537D0 (en) * 1986-04-18 1986-05-21 Ici Plc Polyesters
EP0248531A3 (en) * 1986-05-02 1988-09-28 Southern Research Institute Encapsulated nucleic acids
CA1257199A (en) * 1986-05-20 1989-07-11 Paul Y. Wang Preparation containing bioactive macromolecular substance for multi-months release in vivo
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US6150328A (en) 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
JPH0725689B2 (ja) * 1986-10-07 1995-03-22 中外製薬株式会社 顆粒球コロニ−刺激因子を含有する徐放性製剤
US6024983A (en) * 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US4981696A (en) * 1986-12-22 1991-01-01 E. I. Du Pont De Nemours And Company Polylactide compositions
DE3701625A1 (de) * 1987-01-21 1988-08-04 Boehringer Ingelheim Kg Perorale arzneimittelzubereitung mit verzoegerter wirkstofffreigabe
DE3710175A1 (de) * 1987-02-12 1988-08-25 Hoechst Ag Mehrteilige implantierbare arzneizubereitung mit langzeitwirkung
AU606383B2 (en) * 1987-03-06 1991-02-07 Research Triangle Institute Polymer blends for selective biodegradability
US5028430A (en) * 1987-05-08 1991-07-02 Syntex (U.S.A.) Inc. Delivery systems for the controlled administration of LHRH analogs
US5000886A (en) * 1987-05-26 1991-03-19 American Cyanamid Company Silicone-hardened pharmaceutical microcapsules and process of making the same
DE3822557C2 (de) * 1987-07-10 1998-07-02 Ciba Geigy Ag Arzneimittel, enthaltend Somatostatine
GB8716324D0 (en) * 1987-07-10 1987-08-19 Sandoz Ltd Organic compounds
US4866226A (en) * 1987-07-13 1989-09-12 Mitsubishi Denki Kabushiki Kaisha Multi-phase circuit breaker employing arc extinguishing apparatus
JPH0613602B2 (ja) * 1987-07-14 1994-02-23 三井東圧化学株式会社 ｄ▲ｌ▼−乳酸−グリコール酸共重合物の製造方法
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5212154A (en) * 1987-08-14 1993-05-18 Akzo N.V. Preparation for treating complications in diabetes
NZ226171A (en) * 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
US5457093A (en) * 1987-09-18 1995-10-10 Ethicon, Inc. Gel formulations containing growth factors
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US5187150A (en) * 1987-10-14 1993-02-16 Debiopharm S.A. Polyester-based composition for the controlled release of polypeptide medicinal substances
JP2670680B2 (ja) * 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
US4902515A (en) * 1988-04-28 1990-02-20 E. I. Dupont De Nemours And Company Polylactide compositions
FR2634770B1 (fr) * 1988-07-29 1990-10-05 Rhone Poulenc Chimie Composition polyester erodable contenant de l'iode pour le traitement des eaux
US6323307B1 (en) 1988-08-08 2001-11-27 Cargill Dow Polymers, Llc Degradation control of environmentally degradable disposable materials
US5252642A (en) * 1989-03-01 1993-10-12 Biopak Technology, Ltd. Degradable impact modified polyactic acid
US5444113A (en) * 1988-08-08 1995-08-22 Ecopol, Llc End use applications of biodegradable polymers
US5424346A (en) * 1988-08-08 1995-06-13 Ecopol, Llc Biodegradable replacement of crystal polystyrene
US5180765A (en) * 1988-08-08 1993-01-19 Biopak Technology, Ltd. Biodegradable packaging thermoplastics from lactides
US5216050A (en) * 1988-08-08 1993-06-01 Biopak Technology, Ltd. Blends of polyactic acid
US5502158A (en) * 1988-08-08 1996-03-26 Ecopol, Llc Degradable polymer composition
US5250584A (en) * 1988-08-31 1993-10-05 G-C Dental Industrial Corp. Periodontium-regenerative materials
US5633002A (en) * 1988-10-04 1997-05-27 Boehringer Ingelheim Gmbh Implantable, biodegradable system for releasing active substance
US5247013A (en) * 1989-01-27 1993-09-21 Mitsui Toatsu Chemicals, Inc. Biocompatible polyester and production thereof
US4990336A (en) * 1989-02-08 1991-02-05 Biosearch, Inc. Sustained release dosage form
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
ES2077675T3 (es) * 1989-03-10 1995-12-01 Endorecherche Inc Terapia combinada para el tratamiento de enfermedades sensibles a los estrogenos.
NZ234227A (en) * 1989-06-30 1991-08-27 Smithkline Beecham Corp Delayed release dosage form
KR920703065A (ko) * 1989-07-07 1992-12-17 원본미기재 안드로겐 관련질병의 치료방법
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
ATE170753T1 (de) * 1989-07-07 1998-09-15 Endorecherche Inc Androgenderivate zur hemming der aktivität der sexualsteroide
HU221294B1 (en) * 1989-07-07 2002-09-28 Novartis Ag Process for producing retarde compositions containing the active ingredient in a polymeric carrier
CH679207A5 (forum.php) * 1989-07-28 1992-01-15 Debiopharm Sa
US5439688A (en) * 1989-07-28 1995-08-08 Debio Recherche Pharmaceutique S.A. Process for preparing a pharmaceutical composition
US5225205A (en) * 1989-07-28 1993-07-06 Debiopharm S.A. Pharmaceutical composition in the form of microparticles
DE59003337D1 (de) * 1989-10-16 1993-12-09 Danubia Petrochem Polymere Pressling mit retardierter Wirkstofffreisetzung.
US5126147A (en) * 1990-02-08 1992-06-30 Biosearch, Inc. Sustained release dosage form
DK0528978T3 (da) * 1990-05-16 2003-02-17 Southern Res Inst Mikrokapsler til reguleret afgivelse og deres anvendelse i stimulering af nervefibervækst
US6517859B1 (en) 1990-05-16 2003-02-11 Southern Research Institute Microcapsules for administration of neuroactive agents
CA2046830C (en) * 1990-07-19 1999-12-14 Patrick P. Deluca Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
US5620959A (en) * 1990-07-31 1997-04-15 Glaxo Wellcome Inc. Bombesin antagonists
US6353030B1 (en) 1990-08-01 2002-03-05 Novartis Ag Relating to organic compounds
GB9016885D0 (en) * 1990-08-01 1990-09-12 Scras Sustained release pharmaceutical compositions
ZA918168B (en) * 1990-10-16 1993-04-14 Takeda Chemical Industries Ltd Prolonged release preparation and polymers thereof.
US5342557A (en) * 1990-11-27 1994-08-30 United States Surgical Corporation Process for preparing polymer particles
US7285531B1 (en) * 1991-04-10 2007-10-23 Acorda Therapeutics, Inc. Method for prophylaxis or treatment of a nervous system, pathophysiological condition involving a glial growth factor sensitive cell by administration of a glial growth factor
US5403595A (en) * 1991-05-07 1995-04-04 Dynagen, Inc. Controlled, sustained release delivery system for smoking cessation
US5486362A (en) * 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
HU222501B1 (hu) * 1991-06-28 2003-07-28 Endorecherche Inc. MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására
ZA924811B (en) * 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
EP0612348B1 (en) 1991-11-04 2003-04-23 Genetics Institute, LLC Recombinant bone morphogenetic protein heterodimers, compositions and methods of use
US5876452A (en) * 1992-02-14 1999-03-02 Board Of Regents, University Of Texas System Biodegradable implant
US6013853A (en) * 1992-02-14 2000-01-11 The University Of Texas System Continuous release polymeric implant carrier
CA2129514A1 (en) * 1992-03-12 1993-09-16 M. Amin Khan Controlled released acth containing microspheres
US5912015A (en) * 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
US5429822A (en) * 1992-03-13 1995-07-04 Cambridge Scientific, Inc. Biodegradable bursting release system
US5780051A (en) * 1992-04-02 1998-07-14 Dynagen, Inc. Methods and articles of manufacture for nicotine cessation and monitoring nicotine use
JPH07506575A (ja) * 1992-05-21 1995-07-20 アンドルシェルシュ・インコーポレイテッド テストステロン５α−レダクターゼ活性の阻害剤
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
US20030035845A1 (en) * 1992-06-11 2003-02-20 Zale Stephen E. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) * 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) * 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
JP2651320B2 (ja) * 1992-07-16 1997-09-10 田辺製薬株式会社 徐放性マイクロスフェア製剤の製造方法
FR2693905B1 (fr) * 1992-07-27 1994-09-02 Rhone Merieux Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
US5922340A (en) * 1992-09-10 1999-07-13 Children's Medical Center Corporation High load formulations and methods for providing prolonged local anesthesia
US5281419A (en) * 1992-09-28 1994-01-25 Thomas Jefferson University Biodegradable drug delivery system for the prevention and treatment of osteomyelitis
CA2150803C (en) * 1992-12-02 2006-01-31 Henry Auer Controlled release growth hormone containing microspheres
TW333456B (en) * 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
UA61046C2 (en) 1992-12-07 2003-11-17 Takeda Chemical Industries Ltd Sustained-release preparation and method for its manufacture
US6221958B1 (en) 1993-01-06 2001-04-24 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5672659A (en) * 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
AU680650B2 (en) * 1993-01-06 1997-08-07 Ipsen Manufacturing Ireland Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5863985A (en) * 1995-06-29 1999-01-26 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5456917A (en) * 1993-04-12 1995-10-10 Cambridge Scientific, Inc. Method for making a bioerodible material for the sustained release of a medicament and the material made from the method
GB9310030D0 (en) * 1993-05-15 1993-06-30 Scras Dry processed particles and process for the preparation of the same
US5569467A (en) * 1993-05-15 1996-10-29 Societe De Conseils De Recherches Et D'applications (S.C.R.A.S.) Process for the preparation of microballs and microballs thus obtained
US6440457B1 (en) 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
US5635216A (en) * 1993-12-16 1997-06-03 Eli Lilly And Company Microparticle compositions containing peptides, and methods for the preparation thereof
CA2163860A1 (en) * 1993-06-30 1995-01-12 Chung C. Hsu Method for preparing liposomes
CA2170641C (en) 1993-08-30 2011-11-15 James R. Smith Senescent cell-derived inhibitors of dna synthesis
US6291206B1 (en) 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
US5496923A (en) * 1993-09-20 1996-03-05 Mitsui Toatsu Chemicals, Inc. Purification process of aliphatic polyester
US6913767B1 (en) 1993-10-25 2005-07-05 Genentech, Inc. Compositions for microencapsulation of antigens for use as vaccines
US5643605A (en) * 1993-10-25 1997-07-01 Genentech, Inc. Methods and compositions for microencapsulation of adjuvants
US6080429A (en) * 1993-10-25 2000-06-27 Genentech, Inc. Method for drying microspheres
AU689184B2 (en) 1993-12-07 1998-03-26 Genetics Institute, Llc BMP-12, BMP-13 and tendon-inducing compositions thereof
US5942496A (en) * 1994-02-18 1999-08-24 The Regent Of The University Of Michigan Methods and compositions for multiple gene transfer into bone cells
US5763416A (en) * 1994-02-18 1998-06-09 The Regent Of The University Of Michigan Gene transfer into bone cells and tissues
US6074840A (en) * 1994-02-18 2000-06-13 The Regents Of The University Of Michigan Recombinant production of latent TGF-beta binding protein-3 (LTBP-3)
US5962427A (en) * 1994-02-18 1999-10-05 The Regent Of The University Of Michigan In vivo gene transfer methods for wound healing
US20020193338A1 (en) * 1994-02-18 2002-12-19 Goldstein Steven A. In vivo gene transfer methods for wound healing
DE4406172C2 (de) * 1994-02-25 2003-10-02 Sanol Arznei Schwarz Gmbh Polyester
US6551618B2 (en) * 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US5708142A (en) 1994-05-27 1998-01-13 Genentech, Inc. Tumor necrosis factor receptor-associated factors
GB9412273D0 (en) 1994-06-18 1994-08-10 Univ Nottingham Administration means
US6093697A (en) * 1994-11-07 2000-07-25 The University Of Virginia Patent Foundation Synthetic insulin mimetic substances
US5607686A (en) * 1994-11-22 1997-03-04 United States Surgical Corporation Polymeric composition
JPH11501027A (ja) * 1995-02-28 1999-01-26 イナファーマ，インコーポレイテッド 骨粗鬆症の処置のためのエルカトニン制御放出ミクロスフェア処方物
US5665702A (en) * 1995-06-06 1997-09-09 Biomeasure Incorporated Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
US6479457B2 (en) * 1995-06-06 2002-11-12 Kinerton Limited Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US5674888A (en) * 1995-06-07 1997-10-07 University Of California Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division
US5747058A (en) * 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US7833543B2 (en) * 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US5599535A (en) * 1995-06-07 1997-02-04 Regents Of The University Of California Methods for the cyto-protection of the trabecular meshwork
US5968542A (en) * 1995-06-07 1999-10-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system as a device
NZ311474A (en) 1995-06-09 1997-09-22 Euro Celtique Sa Formulations for providing prolonged local anesthesia
US5955574A (en) 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6020473A (en) * 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
US7005505B1 (en) 1995-08-25 2006-02-28 Genentech, Inc. Variants of vascular endothelial cell growth factor
EP0789045B1 (en) * 1995-08-29 2001-01-10 Kyowa Hakko Kogyo Co., Ltd. Process for producing polyhydroxy carboxylic acid
JP2000507912A (ja) * 1995-08-31 2000-06-27 アルカームズ コントロールド セラピューティックス，インコーポレイテッド 作用剤の徐放性組成物
US5942253A (en) 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
CA2192773C (en) 1995-12-15 2008-09-23 Hiroaki Okada Production of sustained-release preparation for injection
US5980945A (en) * 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
AU1732897A (en) * 1996-02-23 1997-09-10 Kyowa Hakko Kogyo Co. Ltd. Process for the preparation of polyhydroxycarboxylic acid
US5747060A (en) * 1996-03-26 1998-05-05 Euro-Celtique, S.A. Prolonged local anesthesia with colchicine
IE960308A1 (en) * 1996-04-23 1997-11-05 Kinerton Ltd Sustained release ionic conjugate
JP3155013B2 (ja) * 1996-04-23 2001-04-09 キナートン・リミテッド 酸性ポリ乳酸ポリマー
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US5766877A (en) * 1996-05-10 1998-06-16 Amgen Inc. Genes encoding art, an agouti-related transcript
US5817343A (en) * 1996-05-14 1998-10-06 Alkermes, Inc. Method for fabricating polymer-based controlled-release devices
AU733867B2 (en) 1996-06-24 2001-05-31 Euro-Celtique S.A. Methods for providing safe local anesthesia
US6046187A (en) 1996-09-16 2000-04-04 Children's Medical Center Corporation Formulations and methods for providing prolonged local anesthesia
US5952455A (en) * 1996-10-11 1999-09-14 Kyowa Hakko Kogyo Co., Ltd. Process for producing polyhydroxycarboxylic acid
EP0939804B2 (en) 1996-10-25 2011-06-15 Human Genome Sciences, Inc. NEUTROKINE alpha
ES2221019T3 (es) * 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
US6156728A (en) 1996-11-01 2000-12-05 Genentech, Inc. Treatment of inner ear hair cells
US6593290B1 (en) 1996-11-01 2003-07-15 Genentech, Inc. Treatment of inner ear hair cells
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
US5919656A (en) 1996-11-15 1999-07-06 Amgen Canada Inc. Genes encoding telomerase protein 1
US7390891B1 (en) 1996-11-15 2008-06-24 Amgen Inc. Polynucleotides encoding a telomerase component TP2
US20020111603A1 (en) 1996-12-02 2002-08-15 Societe De Conseils De Recherches Et D'application Device for local administration of solid or semi-solid formulations and delayed-release formulations for proposal parental administration and preparation process
US7138511B1 (en) 1997-01-28 2006-11-21 The Regents Of The University Of California Nucleic acids, kits and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US6171788B1 (en) 1997-01-28 2001-01-09 The Regents Of The University Of California Methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US6475724B1 (en) 1997-01-28 2002-11-05 The Regents Of The University Of California Nucleic acids, kits, and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US7235524B2 (en) * 1997-01-31 2007-06-26 Applied Research System Ars Holding N.V. Medicaments for initiating ovulation
US5945126A (en) * 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
US6071982A (en) * 1997-04-18 2000-06-06 Cambridge Scientific, Inc. Bioerodible polymeric semi-interpenetrating network alloys for surgical plates and bone cements, and method for making same
US20060025328A1 (en) * 1997-05-28 2006-02-02 Burns Patrick J Compositions suitable for controlled release of the hormone GnRH and its analogs
ATE487737T1 (de) 1997-05-30 2010-11-15 Human Genome Sciences Inc 32 humane sekretierte proteine
US6867181B1 (en) 1997-06-02 2005-03-15 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US6663899B2 (en) 1997-06-13 2003-12-16 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6113947A (en) * 1997-06-13 2000-09-05 Genentech, Inc. Controlled release microencapsulated NGF formulation
BR9815499A (pt) 1997-07-02 2001-01-02 Euro Celtique Sa Anestesia prolongada nas juntas e nos espacos corporais.
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US6994851B1 (en) 1997-07-10 2006-02-07 Mannkind Corporation Method of inducing a CTL response
US7923250B2 (en) 1997-07-30 2011-04-12 Warsaw Orthopedic, Inc. Methods of expressing LIM mineralization protein in non-osseous cells
CA2297489A1 (en) * 1997-07-30 1999-02-11 Emory University Novel bone mineralization proteins, dna, vectors, expression systems
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
WO1999014240A1 (en) 1997-09-17 1999-03-25 Human Genome Sciences, Inc. Interleukin-17 receptor-like protein
ATE233097T1 (de) 1997-11-07 2003-03-15 Chiron Corp Verfahren zur herstellung von igf-i formulierungen mit verzögerter freisetzung
US6372880B1 (en) 1997-12-25 2002-04-16 Mitsui Chemicals, Inc. Copolymer and process for preparing the same
US5906979A (en) * 1998-01-27 1999-05-25 Insmed Pharmaceuticals, Inc. Compositions and methods for treating metabolic diseases characterized by hyperandrogenism and/or anovulation and/or infertility
AR014069A1 (es) 1998-01-29 2001-01-31 Kinerton Ltd Procedimiento para preparar microparticula o microparticulas unidas encapsuladas
PL193111B1 (pl) * 1998-01-29 2007-01-31 Poly Med Inc Związana mikrocząstka, otoczona mikrocząstka zawierająca co najmniej jedną związaną mikrocząstkę, kompozycja farmaceutyczna zawierająca związaną mikrocząstkę lub otoczoną mikrocząstkę oraz sposób wytwarzania otoczonej mikrocząstki
NZ525914A (en) 1998-03-10 2004-03-26 Genentech Inc Novel polypeptides and nucleic acids encoding the same
US20030180368A1 (en) * 1998-03-14 2003-09-25 Cenes Drug Delivery Limited Production of microparticles
DK2016951T3 (da) 1998-03-17 2012-09-24 Genentech Inc VEGF- og BMP1-homologe polypeptider
DE69943022D1 (de) 1998-03-19 2011-01-20 Human Genome Sciences Rockville Der gemeinsamen gamma-kette ähnlicher zytokinrezeptor
AR020650A1 (es) * 1998-08-10 2002-05-22 Poly Med Inc Polimeros fosforilados y conjugados de los mismos
US7662409B2 (en) * 1998-09-25 2010-02-16 Gel-Del Technologies, Inc. Protein matrix materials, devices and methods of making and using thereof
US6344541B1 (en) 1998-09-25 2002-02-05 Amgen Inc. DKR polypeptides
US20030007991A1 (en) * 1998-09-25 2003-01-09 Masters David B. Devices including protein matrix materials and methods of making and using thereof
HUP0103773A3 (en) 1998-10-09 2003-10-28 Biogen Idec Ma Inc Cambridge Reversal of viral-induced systemic schock and respiratory distress by blockade of the lymphotoxin beta pathway
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6270802B1 (en) 1998-10-28 2001-08-07 Oakwood Laboratories L.L.C. Method and apparatus for formulating microspheres and microcapsules
WO2000025826A1 (en) 1998-11-02 2000-05-11 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Lactone bearing absorbable polymers
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6365173B1 (en) 1999-01-14 2002-04-02 Efrat Biopolymers Ltd. Stereocomplex polymeric carriers for drug delivery
US6303749B1 (en) 1999-01-29 2001-10-16 Amgen Inc. Agouti and agouti-related peptide analogs
US6727224B1 (en) 1999-02-01 2004-04-27 Genetics Institute, Llc. Methods and compositions for healing and repair of articular cartilage
US7708993B2 (en) 1999-02-03 2010-05-04 Amgen Inc. Polypeptides involved in immune response
US8624010B1 (en) 1999-02-03 2014-01-07 Steven K. Yoshinaga Nucleic acids encoding B7RP1
SI2332978T1 (sl) 1999-02-03 2014-08-29 Amgen Inc. Novi polipeptidi, vkljuäśeni v imunskem odgovoru
US7435796B1 (en) 1999-02-03 2008-10-14 Amgen Inc. Antibodies which bind B7RP1
EP1161451A4 (en) 1999-02-26 2006-05-17 Human Genome Sciences Inc HUMAN ALPHA ENDOKIN AND METHOD FOR ITS USE
ES2242604T3 (es) 1999-02-26 2005-11-16 Chiron Corporation Microemulsiones con macroparticulas y microparticulas adsorbidas.
JP2002539172A (ja) 1999-03-17 2002-11-19 ノバルティス アクチエンゲゼルシャフト Ｔｇｆ−ベータを含む医薬組成物
WO2000058479A1 (en) 1999-03-26 2000-10-05 Amgen Inc. Beta secretase genes and polypeptides
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
US20030166561A1 (en) * 1999-06-18 2003-09-04 Cooper Garth J. S. Peptide
MXPA01013236A (es) 1999-06-28 2002-06-21 Genentech Inc Metodos para hacer ligando apo-2 mediante el uso de iones metalicos divalentes.
US7713739B1 (en) * 2000-11-17 2010-05-11 Novartis Vaccines And Diagnostics, Inc. Microparticle-based transfection and activation of dendritic cells
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US7408047B1 (en) 1999-09-07 2008-08-05 Amgen Inc. Fibroblast growth factor-like polypeptides
PT1223990E (pt) 1999-10-15 2004-12-31 Fidia Advanced Biopolymers Srl Formulacoes de acido hialuronico para administracao de proteinas osteogenicas
US7078382B1 (en) 1999-11-02 2006-07-18 Genentech, Inc. Modulation of eNOS activity and therapeutic uses thereof
US6682754B2 (en) 1999-11-24 2004-01-27 Willmar Poultry Company, Inc. Ovo delivery of an immunogen containing implant
US6465425B1 (en) 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
US20030103978A1 (en) 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
ES2266187T3 (es) * 2000-03-24 2007-03-01 Genentech, Inc. Uso de la insulina para el tratamiento de trastornos del cartilago.
US7514239B2 (en) 2000-03-28 2009-04-07 Amgen Inc. Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
EP2213743A1 (en) 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albumin fusion proteins
EP1289512B1 (en) * 2000-05-24 2005-03-09 Jordan L. Holtzman Agents and methods for increasing brain chaperonin levels
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US20040170665A1 (en) * 2000-06-02 2004-09-02 Allergan, Inc. Intravitreal botulinum toxin implant
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
AU2001282856A1 (en) 2000-06-15 2001-12-24 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
EP2168980A1 (en) 2000-06-23 2010-03-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogensis
EP2042597B1 (en) 2000-06-23 2014-05-07 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
DE60137223D1 (de) 2000-06-28 2009-02-12 Amgen Inc Thymus-stroma lymphopoietin rezeptor-moleküle und deren verwendung
AU2001276733A1 (en) 2000-08-07 2002-02-18 Takeda Chemical Industries Ltd. Lactic acid polymer and process for producing the same
US6362308B1 (en) 2000-08-10 2002-03-26 Alkermes Controlled Therapeutics Inc. Ii Acid end group poly(d,l-lactide-co-glycolide) copolymers high glycolide content
US6565888B1 (en) 2000-08-23 2003-05-20 Alkermes Controlled Therapeutics, Inc. Methods and compositions for the targeted delivery of biologically active agents
EP1317283B1 (en) 2000-09-14 2011-07-06 Biogen Idec MA Inc. Tweak receptor agonists as anti-angiogenic agents
CA2423431A1 (en) * 2000-10-06 2002-04-11 Durect Corporation Devices and methods for management of inflammation
DE10055742B4 (de) 2000-11-10 2006-05-11 Schwarz Pharma Ag Neue Polyester, Verfahren zu ihrer Herstellung und aus den Polyestern hergestellte Depot-Arzneiformen
US8470359B2 (en) 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
JP2006500115A (ja) 2000-11-16 2006-01-05 マイクロスフエリツクス・エル・エル・シー 密封小線源治療用の可撓性および／または弾性シードまたはストランド
WO2002044364A2 (en) 2000-11-28 2002-06-06 Amgen Inc. Polypeptides involved in immune response
US6989247B2 (en) 2000-11-28 2006-01-24 Celltech R & D, Inc. Compositions and methods for diagnosing or treating psoriasis
WO2003053325A2 (en) 2000-12-13 2003-07-03 Purdue Research Foundation Microencapsulation of drugs by solvent exchange
EP1363602A4 (en) * 2001-01-25 2006-01-11 Euro Celtique Sa LOCAL ANESTHESIA, AND METHOD OF USE
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
GB0111628D0 (en) 2001-05-11 2001-07-04 Scancell Ltd Binding member
DK1399023T3 (da) 2001-06-01 2008-08-18 Wyeth Corp Sammensætninger til systemisk indgivelse af sekvenser, der koder for knoglemorfogenese-proteiner
AUPR546801A0 (en) 2001-06-05 2001-06-28 Commonwealth Scientific And Industrial Research Organisation Recombinant antibodies
TWI267378B (en) 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
JP2004535431A (ja) 2001-06-22 2004-11-25 サザン バイオシステムズ， インコーポレイテッド ゼロ次長期放出同軸インプラント
DK2270052T3 (en) 2001-06-26 2018-07-02 Amgen Inc Antibodies to OPGL
AR034641A1 (es) 2001-06-29 2004-03-03 Takeda Pharmaceutical Composicion de liberacion controlada y metodo para producirla
EP2382982A3 (en) 2001-08-24 2012-02-22 Neuren Pharmaceuticals Limited Neural regeneration peptide and methods for their use in treatment of brain damage
CN101884784B (zh) 2001-08-29 2014-03-12 杰南技术公司 具有促细胞分裂活性的Bv8的核酸和多肽
AR036400A1 (es) * 2001-08-30 2004-09-08 Stem Cell Therapeutics Inc Regulacion combinada de la produccion de celulas nerviosas.
GB0122113D0 (en) * 2001-09-11 2001-10-31 Astrazeneca Ab Composition
CA2460184A1 (en) * 2001-09-14 2003-03-27 Stem Cell Therapeutics Inc. Prolactin induced increase in neural stem cell numbers and therapeutical use thereof
AR036402A1 (es) * 2001-09-18 2004-09-08 Stem Cell Therapeutics Inc Efecto de la hormona de crecimiento y de igf-1 sobre celulas madre neuronales.
CA2461345A1 (en) 2001-09-24 2003-04-03 Imperial College Innovations Ltd. Use of pyy or agonist thereof to modify feeding behaviour
CA2461292A1 (en) 2001-10-02 2003-04-10 Genentech, Inc. Apo-2 ligand variants and uses thereof
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
ES2321701T3 (es) 2001-10-12 2009-06-10 Schering Corporation Uso de anticuerpos biespecificos que se unen al receptor de activacion fcepsilonri y al receptor de inhibicion ox2ra (cd200ra) para regular respuestas inmunes.
EP2322165A1 (en) 2001-11-13 2011-05-18 Genentech, Inc. Apo2 ligand/TRAIL formulations
NZ533434A (en) * 2001-11-14 2006-11-30 Alza Corp Thixotropic gel composition for injectable deposition
CU23043A1 (es) 2001-12-20 2005-05-20 Ct Ingenieria Genetica Biotech Composicion farmaceutica que contiene factor de crecimiento epidrmico (egf) para la prevencion de la amputacion de pie diabetico.
CA2841097A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
US8058233B2 (en) 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
CA2472882A1 (en) 2002-01-10 2003-07-17 Imperial College Innovations Ltd Use of pyy and glp-1, or an agonist thereof, for the modification of feeding behaviour
US7662924B2 (en) 2002-02-22 2010-02-16 The Board Of Trustees Of The University Of Illinois Beta chain-associated regulator of apoptosis
AU2003225895A1 (en) * 2002-03-19 2003-10-08 Purdue Research Foundation Microencapsulation using ultrasonic atomizers
JP4761710B2 (ja) 2002-04-05 2011-08-31 アムジェン インコーポレイテッド 選択的ｏｐｇｌ経路インヒビターとしてのヒト抗ｏｐｇｌ中和抗体
JP4386741B2 (ja) 2002-04-15 2009-12-16 中外製薬株式会社 ｓｃＤｂライブラリーの作成方法
DE60327199D1 (de) 2002-04-26 2009-05-28 Chugai Pharmaceutical Co Ltd Verfahren zum screening auf agonistische antikörper
CA2483778A1 (en) 2002-04-29 2003-11-13 Gel-Del Technologies, Inc. Biomatrix structural containment and fixation systems and methods of use thereof
AU2002304965A1 (en) 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
EP2305710A3 (en) 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
DE10227232A1 (de) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
WO2004001009A2 (en) 2002-06-24 2003-12-31 Genentech, Inc. Apo-2 ligand/trail variants and uses thereof
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
EP1546198A1 (en) * 2002-07-31 2005-06-29 Stem Cell Therapeutics Inc. Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (pacap)
US20040142393A1 (en) * 2002-08-01 2004-07-22 Cooper Garth James Smith Methods of use of compounds with preptin function
US8075585B2 (en) * 2002-08-29 2011-12-13 Stryker Corporation Device and method for treatment of a vascular defect
RS52889B (sr) 2002-09-06 2014-02-28 Amgen Inc Terapijsko humano anti-il-1r1 monoklonsko antitelo
AU2003285874A1 (en) 2002-10-16 2004-05-04 Amgen Inc. HUMAN ANTI-IFN-Gamma NEUTRALIZING ANTIBODIES AS SELECTIVE IFN-Gamma PATHWAY INHIBITORS
US20040086532A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
PL377342A1 (pl) 2002-11-15 2006-01-23 Idenix (Cayman) Limited Nukleozydy rozgałęzione w pozycji 2' oraz mutacja Flaviviridae
WO2004050683A2 (en) 2002-12-02 2004-06-17 Abgenix, Inc. Antibodies directed to tumor necrosis factor and uses thereof
EP2218448B1 (en) * 2002-12-13 2015-09-23 Durect Corporation Oral drug delivery system comprising high viscosity liquid carrier materials
US7022481B2 (en) 2002-12-19 2006-04-04 Rosetta Inpharmatics Llc Methods of using glucan synthase pathway reporter genes to screen for antifungal compounds
PL378879A1 (pl) 2002-12-30 2006-05-29 Amgen Inc. Terapia skojarzona z czynnikami kostymulującymi
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
EP1440992A1 (fr) * 2003-01-21 2004-07-28 Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) Système catalytique de (co)polymérisation du lactide et du glycolide
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
DK1911763T3 (da) 2003-01-28 2010-11-15 Ironwood Pharmaceuticals Inc Sammensætninger til behandling af mavetarmsygdomme
GB0304726D0 (en) * 2003-03-01 2003-04-02 Ardana Bioscience Ltd New Process
EP2853593B1 (en) 2003-03-07 2017-10-04 DSM IP Assets B.V. Hydrolases, nucleic acids encoding them and mehods for making and using them
NZ541480A (en) 2003-03-12 2008-03-28 Genentech Inc Use of Bv8 and/or EG-VEGF to promote hematopoiesis
US20060076295A1 (en) * 2004-03-15 2006-04-13 The Trustees Of Columbia University In The City Of New York Systems and methods of blood-based therapies having a microfluidic membraneless exchange device
WO2004082796A2 (en) * 2003-03-14 2004-09-30 The Trustees Of Columbia University In The City Ofnew York Systems and methods of blood-based therapies having a microfluidic membraneless exchange device
DK1613750T3 (en) 2003-03-19 2016-01-18 Amgen Fremont Inc ANTIBODIES TO T CELL AND MUCINDO immunoglobulin-binding domain 1 (TIM-1) antigen and uses thereof
DK1606409T3 (da) 2003-03-19 2011-01-03 Biogen Idec Inc Nogo-receptorbindende protein
CN1809584B (zh) * 2003-04-25 2010-12-01 诺华疫苗和诊断公司 含有阳离子微粒和hcv e1e2 dna的组合物及其使用方法
US7259234B2 (en) 2003-05-15 2007-08-21 Trustees Of Tufts College Stable analogs of peptide and polypeptide therapeutics
WO2004103313A2 (en) 2003-05-20 2004-12-02 The American National Red Cross Methods of reducing vascular permeability in tissue by inhibition of tissue plasminogen activator (tpa) and tpa inhibitors useful therein
BRPI0411803A (pt) 2003-06-27 2006-05-23 Abgenix Inc anticorpos dirigidos aos mutantes de deleção de receptor de fator de crescimento epidérmico e seus usos
PL1648998T3 (pl) 2003-07-18 2015-03-31 Amgen Inc Specyficzne czynniki wiążące czynnik wzrostu hepatocytów
JP2008518881A (ja) 2003-07-18 2008-06-05 オークウッド ラボラトリーズ，エル．エル．シー． 高分子組成物中の高分子の分子量低下、不純物形成およびゲル化の防止
US8541051B2 (en) * 2003-08-14 2013-09-24 Halliburton Energy Services, Inc. On-the fly coating of acid-releasing degradable material onto a particulate
US9149440B2 (en) * 2003-09-02 2015-10-06 University Of South Florida Nanoparticles for drug-delivery
GB0320806D0 (en) * 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
AU2004272072B2 (en) 2003-09-12 2010-07-08 Etex Corporation Injectable calcium phosphate solid rods and pastes for delivery of osteogenic proteins
AU2004291833B2 (en) 2003-09-12 2010-08-26 Ipsen Biopharmaceuticals, Inc. Methods for treatment of insulin-like growth factor-1 (IGF-1) deficiency
WO2005035753A1 (ja) 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 機能蛋白質を代替する二重特異性抗体
US7783006B2 (en) * 2003-10-10 2010-08-24 Xoft, Inc. Radiation treatment using x-ray source
US20050080313A1 (en) * 2003-10-10 2005-04-14 Stewart Daren L. Applicator for radiation treatment of a cavity
US7309232B2 (en) * 2003-10-10 2007-12-18 Dentigenix Inc. Methods for treating dental conditions using tissue scaffolds
US20080075712A1 (en) 2003-10-14 2008-03-27 Kunihiro Hattori Double Specific Antibodies Substituting For Functional Proteins
WO2005044188A2 (en) 2003-10-27 2005-05-19 Amgen Inc. Compositions and methods to modulate an immune response to an immunogenic therapeutic agent
WO2005044817A1 (en) 2003-11-05 2005-05-19 Sunesis Pharmaceuticals, Inc. Modulators of cellular adhesion
WO2005067889A1 (en) * 2003-12-30 2005-07-28 Durect Corporation Polymeric implants, preferably containing a mixture of peg and plg, for controlled release of active agents, preferably a gnrh
CN100534527C (zh) * 2003-12-30 2009-09-02 杜雷科特公司 用于控制释放优选为GnRH的活性剂的优选含有PEG和PLG的混合物的聚合植入物
CA2551082A1 (en) * 2004-01-07 2005-07-28 Trimeris, Inc. Hiv gp41 hr2-derived synthetic peptides, and their use in therapy to inhibit transmission of human immunodeficiency virus
CA2553035A1 (en) 2004-02-02 2005-08-18 Ambrx, Inc. Modified human growth hormone polypeptides and their uses
US20070066525A1 (en) * 2004-02-04 2007-03-22 Lee John C Compositions and therapeutic methods using morphogenic proteins
CA2556266A1 (en) 2004-02-13 2005-08-25 Stem Cell Therapeutics Corp. Use of luteinizing hormone (lh), and chorionic gonadotropin (hcg) for proliferation of neural stem cells and neurogenesis
JP2008507257A (ja) 2004-03-19 2008-03-13 アムゲン・インコーポレーテッド Ｖ遺伝子の操作を介したヒト抗ヒト抗体の危険性の低減
JP4705026B2 (ja) 2004-03-19 2011-06-22 ジェノミディア株式会社 血管内皮増殖促進遺伝子
CN1980957A (zh) 2004-03-23 2007-06-13 比奥根艾迪克Ma公司 受体偶联剂及其治疗用途
GB0410627D0 (en) 2004-05-12 2004-06-16 Scancell Ltd Specific binding members
EP1598428A1 (en) 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
AU2005247943A1 (en) 2004-05-23 2005-12-08 Gerard M. Housey Theramutein modulators
EP2298335B1 (en) 2004-05-25 2014-09-03 Stryker Corporation Use of OP-1 for treating cartilage defects
CN102532321B (zh) 2004-06-18 2018-10-12 Ambrx公司 新颖抗原结合多肽和其用途
EP1758999B1 (en) 2004-06-22 2011-03-09 The Board Of Trustees Of The University Of Illinois METHODS OF INHIBITING TUMOR CELL PROLIFERATION WITH FOXM1 siRNA
PL1776136T3 (pl) 2004-06-24 2013-03-29 Biogen Ma Inc Leczenie stanów związanych z demielinizacją
WO2006004774A2 (en) * 2004-06-28 2006-01-12 Stanford University Laulimalide analogues as therapeutic agents
US20060004185A1 (en) * 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
ME00226B (me) 2004-07-15 2011-02-10 Medarex Llc Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
CA2569381A1 (en) 2004-07-21 2006-08-31 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
US7846438B2 (en) 2004-08-03 2010-12-07 Biogen Idec Ma Inc. Methods of promoting neurite outgrowth with soluble TAJ polypeptides
ES2414460T3 (es) 2004-08-04 2013-07-19 Amgen Inc. Anticuerpos para Dkk-1
CA2575988C (en) * 2004-08-04 2014-02-18 Brookwood Pharmaceuticals, Inc. Methods for manufacturing delivery devices and devices thereof
KR101231856B1 (ko) 2004-08-12 2013-02-08 큐피에스 엘엘씨 생물학적 활성 화합물의 제어 방출 전달용 약학 조성물
CA2577442A1 (en) 2004-08-17 2006-03-02 The Johns Hopkins University Pde5 inhibitor compositions and methods for treating cardiac indications
WO2006029406A2 (en) * 2004-09-09 2006-03-16 Stryker Corporation Methods for treating bone tumors using bone morphogenic proteins
PL2415484T3 (pl) * 2004-09-17 2014-11-28 Durect Corp Kompozycja znieczulająca miejscowo o przedłużonym uwalnianiu zawierająca SAIB
CA2583061C (en) 2004-10-06 2015-02-17 Kwang Guan Tay Antibody production method
FR2876379B1 (fr) * 2004-10-08 2008-09-05 Isochem Sa Procede de polymerisation des o-carboxy anhydrides
WO2006041048A1 (ja) 2004-10-15 2006-04-20 Mie University 肝再生・修復制御剤
ATE492563T1 (de) 2004-11-17 2011-01-15 Amgen Inc Vollständige humane monoklonale antikörper gegen il-13
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
GB0425854D0 (en) * 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
US7572444B2 (en) 2004-12-20 2009-08-11 Amgen Fremont Inc. Binding proteins specific for human matriptase
CN101128483B (zh) 2004-12-21 2015-06-03 阿斯利康公司 血管生成素-2的抗体及其应用
ATE542920T1 (de) 2004-12-22 2012-02-15 Ambrx Inc Modifiziertes menschliches wachstumshormon
AU2005319125A1 (en) 2004-12-22 2006-06-29 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
CN101163464A (zh) * 2004-12-23 2008-04-16 杜雷科特公司 优选含有PEG和PLG混合物的控制释放GnRH的聚合物植入物
EP1838338A2 (en) * 2004-12-29 2007-10-03 Mannkind Corporation Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
CA2590164A1 (en) 2005-01-26 2006-08-03 Amgen Fremont Inc. Antibodies against interleukin-1 beta
MX2007012374A (es) * 2005-04-06 2008-02-22 Adamas Pharmaceuticals Inc Metodos y composiciones para el tratamiento de condiciones relacionadas con cns.
PT1876236E (pt) 2005-04-08 2014-10-22 Chugai Pharmaceutical Co Ltd Anticorpos para substituição da função do factor de coagulação sanguínea viii
WO2006112737A1 (en) * 2005-04-20 2006-10-26 Protemix Discovery Limited Vesiculins
JP2008539260A (ja) * 2005-04-25 2008-11-13 アムジエン・インコーポレーテツド ポロゲンを含む生分解性プチド徐放性組成物
US7342048B2 (en) 2005-04-28 2008-03-11 Nipro Corporation Bioabsorbable pharmaceutical formulation
US7417072B2 (en) 2005-05-12 2008-08-26 Wisconsin Alumni Research Foundation Blockade of Pin1 prevents cytokine production by activated immune cells
EP2444079B1 (en) 2005-05-17 2016-11-30 SARcode Bioscience Inc. Compositions and Methods for Treatment of Eye Disorders
US8431110B2 (en) 2005-05-23 2013-04-30 Hmi Medical Innovations, Llc. Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
TW200718780A (en) 2005-06-10 2007-05-16 Chugai Pharmaceutical Co Ltd Sc(Fv)2 site-directed mutant
JP5068167B2 (ja) 2005-06-10 2012-11-07 中外製薬株式会社 メグルミンを含有するタンパク質製剤の安定化剤、およびその利用
JP2008543839A (ja) 2005-06-14 2008-12-04 アムジェン インコーポレーテッド 自己緩衝タンパク質製剤
CA2612760C (en) 2005-06-21 2015-05-12 Xoma Technology Ltd. Il-1.beta. binding antibodies and fragments thereof
MX2008000253A (es) 2005-07-08 2008-04-02 Biogen Idec Inc Anticuerpos de sp35 y usos de los mismos.
SG164369A1 (en) 2005-07-18 2010-09-29 Amgen Inc Human anti-b7rp1 neutralizing antibodies
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
CN101600475A (zh) 2005-07-27 2009-12-09 佛罗里达大学研究基金会有限公司 修正蛋白质错误折叠的小型化合物及其使用
EP2497781A1 (en) 2005-09-08 2012-09-12 Trustees Of Tufts College Stabilized GLP-1 analogs
AU2006297041A1 (en) 2005-09-27 2007-04-05 Stem Cell Therapeutics Corp. Oligodendrocyte precursor cell proliferation regulated by prolactin
CN101287464A (zh) 2005-09-29 2008-10-15 科学研究和应用咨询股份公司 用于刺激胃肠运动性的组合物和方法
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
KR20080074120A (ko) 2005-10-13 2008-08-12 휴먼 게놈 사이언시즈, 인코포레이티드 자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물
BRPI0617378B8 (pt) 2005-10-14 2022-09-20 Chugai Pharmaceutical Co Ltd Uso de um inibidor de il-6 para produzir uma composição farmacêutica para suprimir dano a um ilhota transplantada depois do transplante de ilhota; e aperfeiçoar a viabilidade de uma ilhota em um transplante de ilhota
JP5191235B2 (ja) 2005-10-21 2013-05-08 中外製薬株式会社 心疾患治療剤
CA2628451A1 (en) 2005-11-04 2007-05-18 Biogen Idec Ma Inc. Methods for promoting neurite outgrowth and survival of dopaminergic neurons
US7942867B2 (en) * 2005-11-09 2011-05-17 The Invention Science Fund I, Llc Remotely controlled substance delivery device
AU2006315580A1 (en) 2005-11-10 2007-05-24 Curagen Corporation Method of treating ovarian and renal cancer using antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen
AR056806A1 (es) 2005-11-14 2007-10-24 Amgen Inc Moleculas quimericas de anticuerpo rankl- pth/ pthrp
JP5398987B2 (ja) 2005-11-14 2014-01-29 セルミド リミテッド 調節性ｔ細胞の機能異常に基づく疾患の治療方法及び予防方法
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
CN106443006A (zh) 2005-11-16 2017-02-22 Ambrx公司 包括非天然氨基酸的方法和组合物
JPWO2007061029A1 (ja) 2005-11-25 2009-05-07 学校法人慶應義塾 前立腺癌治療剤
EP1962901A2 (en) 2005-12-01 2008-09-03 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Compositions and methods relating to treatment of cancer and infectious diseases
US20090175872A1 (en) 2005-12-02 2009-07-09 Biogen Idec Ma Inc. Treatment of Conditions Involving Demyelination
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
WO2008024128A2 (en) 2005-12-05 2008-02-28 Simon Delagrave Loop-variant pdz domains as biotherapeutics, diagnostics and research reagents
WO2007066313A2 (en) 2005-12-05 2007-06-14 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Compositions and methods for modulating an immune response
AU2006326649B2 (en) 2005-12-13 2011-03-24 Medimmune Limited Binding proteins specific for insulin-like growth factors and uses thereof
DE602005023550D1 (de) 2005-12-14 2010-10-21 Licentia Ltd Verwendungen eines neurotrophischen Faktors
EP2518083A3 (en) 2005-12-15 2012-12-05 Medimmune Limited Combination of angiopoietin-2 antagonist and of VEGF-A, KDR and/or FLTL antagonist for treating cancer
EP1981525B1 (en) 2005-12-30 2015-01-21 Zensun (Shanghai) Science and Technology Limited Extended release of neuregulin for improved cardiac function
US20070154546A1 (en) * 2005-12-30 2007-07-05 Zhang Jack Y Sustained release pharmaceutical compositions
US20100167341A1 (en) 2006-01-17 2010-07-01 Dnavec Corporation Novel protein expression system
EP1984009B1 (en) * 2006-01-18 2012-10-24 Qps, Llc Pharmaceutical compositions with enhanced stability
CN103215293B (zh) 2006-01-27 2015-10-28 比奥根Ma公司 Nogo受体拮抗剂
EP1990060B1 (en) 2006-01-27 2016-09-28 Keio University Therapeutic agents for diseases associated involving choroidal neovascularization
CU23388B6 (es) 2006-01-31 2009-07-16 Ct Ingenieria Genetica Biotech Composición farmacéutica de microesferas para prevenir la amputación del pie diabético
US7756524B1 (en) 2006-01-31 2010-07-13 Nextel Communications Inc. System and method for partially count-based allocation of vocoder resources
US20070178138A1 (en) * 2006-02-01 2007-08-02 Allergan, Inc. Biodegradable non-opthalmic implants and related methods
EP1987142A4 (en) 2006-02-02 2009-07-15 Verenium Corp ESTERASES AND ASSOCIATED NUCLEIC ACIDS AND METHODS
PT1989220E (pt) 2006-02-02 2012-03-23 Trimeris Inc Péptidos inibidores de fusão de hiv com propriedades biológicas melhoradas
JP2009530235A (ja) * 2006-03-17 2009-08-27 ステム セル セラピューティクス コーポレイション 神経幹細胞増殖剤および神経幹細胞分化剤の連続投与レジメン
EP1837014A1 (en) * 2006-03-21 2007-09-26 Hexal Ag Subcutaneous implants containing a degradation-resistant polylactide polymer and a LH-RH analogue
WO2007116962A1 (ja) 2006-04-07 2007-10-18 Osaka University 筋再生促進剤
TW200813091A (en) 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
ES2497641T3 (es) 2006-05-17 2014-09-23 The Ludwig Institute For Cancer Research Dirección a la regulación de VEGF-B de transportadores de ácidos grasos para modular enfermedades humanas
WO2007142818A2 (en) 2006-05-17 2007-12-13 Stryker Corporation Use of a soluble morphogenic protein complex for treating cartilage defects
US7403325B2 (en) * 2006-05-19 2008-07-22 Xerox Corporation Electrophoretic display device
CN101534917A (zh) * 2006-05-22 2009-09-16 纽约市哥伦比亚大学理事会 采用萃取流体排出流过滤的微流无膜交换系统和方法
US20100022457A1 (en) 2006-05-26 2010-01-28 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators
WO2007143121A2 (en) 2006-06-01 2007-12-13 President And Fellows Of Harvard College Purification of a bivalently active antibody using a non-chromatographic method
KR101557603B1 (ko) 2006-06-08 2015-10-06 추가이 세이야쿠 가부시키가이샤 염증성 질환의 예방 또는 치료제
GB0611405D0 (en) 2006-06-09 2006-07-19 Univ Belfast FKBP-L: A novel inhibitor of angiogenesis
EP2046435A4 (en) * 2006-07-13 2012-06-27 Medtronic Inc METHOD AND FORMULATIONS FOR OPTIMAL LOCAL ADMINISTRATION OF CELL THERAPY BY MEANS OF MINIMALLY INVASIVE PROCEDURES
KR20090038896A (ko) 2006-07-13 2009-04-21 추가이 세이야쿠 가부시키가이샤 세포사 유도제
EP2047862B9 (en) 2006-07-21 2013-04-10 Chugai Seiyaku Kabushiki Kaisha Remedy for renal disease
AU2007279205B2 (en) 2006-07-28 2013-09-26 Children's Memorial Hospital Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
CL2007002225A1 (es) 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
WO2008019368A2 (en) 2006-08-07 2008-02-14 Teva Biopharmaceuticals Usa, Inc. Albumin-insulin fusion proteins
EP2069396B1 (en) 2006-09-08 2015-10-21 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and their uses
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
WO2008049053A2 (en) 2006-10-20 2008-04-24 Biogen Idec Ma Inc. Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
US8337883B2 (en) 2006-11-03 2012-12-25 Durect Corporation Transdermal delivery systems
EP2102661B1 (en) 2006-11-14 2013-09-18 Genentech, Inc. Modulators of neuronal regeneration
PT2121751T (pt) 2006-12-08 2017-04-18 Lexicon Pharmaceuticals Inc Anticorpos monoclonais contra angptl3
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
NO347209B1 (no) 2006-12-18 2023-07-03 Takeda Pharmaceutical Sammensetning med forlenget frigjøring og fremgangsmåte for å produsere det samme
EP2094306A2 (en) 2006-12-20 2009-09-02 XOMA Technology Ltd. Treatment of il-1-beta related diseases
EA036660B1 (ru) 2007-01-09 2020-12-04 Байоджен Эмэй Инк. АНТИТЕЛО К Sp35 ИЛИ ЕГО АНТИГЕНСВЯЗЫВАЮЩИЙ ФРАГМЕНТ И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ НАРУШЕНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
CN101646459B (zh) 2007-01-23 2014-02-12 国立大学法人信州大学 慢性排斥反应抑制剂
JP5492567B2 (ja) 2007-02-02 2014-05-14 バイオジェン・アイデック・エムエイ・インコーポレイテッド 髄鞘形成およびオリゴデンドロサイト分化を促進するためのセマフォリン６ａの使用
TW201718635A (zh) 2007-03-06 2017-06-01 安美基公司 變異之活動素受體多肽及其用途
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
CL2008000719A1 (es) 2007-03-12 2008-09-05 Univ Tokushima Chugai Seiyaku Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
EP2068909B1 (en) 2007-03-30 2012-04-25 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
JP2010523564A (ja) * 2007-04-03 2010-07-15 トリメリス，インコーポレーテッド 抗ウイルス性ペプチド治療薬の送達のための新規製剤
US20100290982A1 (en) * 2007-04-13 2010-11-18 University Of North Texas Health Science Center At Fort Worth Solid in oil/water emulsion-diffusion-evaporation formulation for preparing curcumin-loaded plga nanoparticles
RU2473331C2 (ru) 2007-04-13 2013-01-27 Юниверсити Оф Норс Техас Хэлс Саенс Сентер Эт Форт Ворс Состав активированных наночастиц plga, загруженных активным средством, для целенаправленной нанотерапии рака
US20110065673A1 (en) 2007-05-11 2011-03-17 Bizen Chemical Co., Ltd. Novel leukotriene receptor agonist
DK2167039T3 (en) 2007-05-18 2017-01-09 Durect Corp Improved depot formulations
US10010612B2 (en) 2007-05-25 2018-07-03 Indivior Uk Limited Sustained delivery formulations of risperidone compounds
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2559319T3 (es) 2007-06-04 2016-02-11 Synergy Pharmaceuticals Inc. Agonistas de guanilato cliclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
GB0710976D0 (en) 2007-06-07 2007-07-18 Bioalvo Am Screening method
DK2170390T3 (en) 2007-06-14 2019-01-21 Biogen Ma Inc NATALIZUMABANTISTIC FORMULATIONS
WO2011084685A2 (en) 2009-12-17 2011-07-14 Children's Medical Center Corporation Saposin-a derived peptides and uses thereof
EP3666284A1 (en) 2007-06-22 2020-06-17 Children's Medical Center, Corp. Methods and uses thereof of a fragment of saposin a
WO2009002193A1 (en) 2007-06-27 2008-12-31 Auckland Uniservices Limited Polypeptides and polynucleotides for artemin and related ligands, and methods of use thereof
JP5424330B2 (ja) 2007-07-26 2014-02-26 国立大学法人大阪大学 インターロイキン６受容体阻害剤を有効成分とする眼炎症疾患治療剤
DE102007036101A1 (de) * 2007-08-01 2009-02-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue glycolidreiche Copolymere
TW200916113A (en) 2007-08-08 2009-04-16 Sod Conseils Rech Applic Method for inhibiting inflammation and pro-inflammatory cytokine/chemokine expression using a ghrelin analogue
BRPI0815368A2 (pt) 2007-08-21 2015-02-10 Amgen Inc "proteinas c-fms humanas a antigeno"
EP2615114B1 (en) 2007-08-23 2022-04-06 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US20090156488A1 (en) 2007-09-12 2009-06-18 Zensun (Shanghai) Science & Technology Limited Use of neuregulin for organ preservation
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
EP2040075A1 (en) 2007-09-24 2009-03-25 Julius-Maximilians-Universität Würzburg Compounds and markers for surface-enhanced raman scattering
WO2009042194A2 (en) * 2007-09-25 2009-04-02 Trimeris, Inc. Methods of synthesis for therapeuthic anti-hiv peptides
EP2497783A3 (en) 2007-09-26 2013-04-17 U3 Pharma GmbH Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
JP2010540618A (ja) * 2007-10-02 2010-12-24 アリエル−ユニバーシティー リサーチ アンド デベロップメント カンパニー リミテッド 幼児の成長および発達を増大するための内在性カンナビノイド
BR122019021238B8 (pt) 2007-10-02 2021-07-27 Chugai Pharmaceutical Co Ltd uso de um inibidor do receptor da interleucina-6 (il-6) no tratamento da doença do enxerto versus hospedeiro (gvhd)
US20090123508A1 (en) * 2007-10-04 2009-05-14 Boston Scientific Scimed, Inc. Implantable Drug Depot for Intrathecal Drug Delivery System for Pain Management
CA2702984C (en) 2007-10-19 2017-04-11 Sarcode Corporation Compositions and methods for treatment of diabetic retinopathy
EP2219620B1 (en) * 2007-11-13 2017-07-19 Surmodics, Inc. Viscous terpolymers as drug delivery platform
KR101581733B1 (ko) 2007-11-16 2015-12-31 더 락커펠러 유니버시티 원섬유 형태의 베타­아밀로이드 단백질에 대해 특이적인 항체
EP2930182A1 (en) 2007-11-20 2015-10-14 Ambrx, Inc. Modified insulin polypeptides and their uses
EP2236604B1 (en) 2007-12-05 2016-07-06 Chugai Seiyaku Kabushiki Kaisha Anti-nr10 antibody and use thereof
AU2008332276B2 (en) 2007-12-05 2014-02-27 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for pruritus
EP2219622A1 (en) * 2007-12-06 2010-08-25 Durect Corporation Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
JPWO2009075344A1 (ja) 2007-12-12 2011-04-28 独立行政法人国立がん研究センター Ｍ−ｃｓｆ受容体を分子標的とするｍｌｌ白血病及びｍｏｚ白血病治療剤、およびその利用
PL2391650T3 (pl) 2007-12-20 2015-03-31 Xoma Us Llc Sposoby leczenia dny
US20090181068A1 (en) 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
JP2011514182A (ja) * 2008-02-04 2011-05-06 ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク 流体分離装置、システム、及び方法
CN103694337B (zh) 2008-02-08 2016-03-02 Ambrx公司 经修饰瘦素多肽和其用途
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
WO2009104706A1 (ja) * 2008-02-22 2009-08-27 東レ株式会社 マイクロ粒子およびその医薬品組成物
US8080562B2 (en) 2008-04-15 2011-12-20 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
FI20080326A0 (fi) 2008-04-30 2008-04-30 Licentia Oy Neurotroofinen tekijä MANF ja sen käytöt
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
TWI528973B (zh) 2008-06-05 2016-04-11 Chugai Pharmaceutical Co Ltd Nerve infiltration inhibitor
PL2307381T3 (pl) 2008-06-09 2021-07-05 Ludwig-Maximilians-Universität München Nowe leki do hamowania agregacji białek związanych z chorobami związanymi z agregacją białka i/lub chorobami neurodegeneracyjnymi
EP2307456B1 (en) 2008-06-27 2014-10-15 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
CA2997870A1 (en) 2008-07-09 2010-01-14 Biogen Ma Inc. Compositions comprising antibodies to lingo or fragments thereof
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
NZ600382A (en) 2008-07-23 2013-11-29 Ambrx Inc Modified bovine G-CSF polypeptides and their uses
DK2326336T3 (en) 2008-07-30 2015-07-27 Mesynthes Ltd Tissue support structures from the extracellular matrix of a preform
US8198062B2 (en) * 2008-08-29 2012-06-12 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
US8357503B2 (en) 2008-08-29 2013-01-22 Bunge Oils, Inc. Hydrolases, nucleic acids encoding them and methods for making and using them
US8153391B2 (en) 2008-08-29 2012-04-10 Bunge Oils, Inc. Hydrolases, nucleic acids encoding them and methods for making and using them
US20100129375A1 (en) 2008-09-10 2010-05-27 Genentech, Inc. Methods for inhibiting ocular angiogenesis
AU2009294415B2 (en) 2008-09-19 2015-09-24 Medimmune Llc Antibodies directed to DLL4 and uses thereof
EA019653B1 (ru) 2008-09-26 2014-05-30 Амбркс Инк. Модифицированные полипептиды эритропоэтина животных и их применение
US9121024B2 (en) 2008-09-26 2015-09-01 Ambrx, Inc. Non-natural amino acid replication-dependent microorganisms and vaccines
UA105016C2 (uk) 2008-10-10 2014-04-10 Амген Інк. Fgf21 мутанти і їх застосування
AU2009303304A1 (en) 2008-10-10 2010-04-15 Anaphore, Inc. Polypeptides that bind TRAIL-RI and TRAIL-R2
SG195557A1 (en) 2008-10-22 2013-12-30 Genentech Inc Modulation of axon degeneration
CA2738243C (en) 2008-10-29 2020-09-29 Wyeth Llc Formulations of single domain antigen binding molecules
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
US8722052B2 (en) 2008-11-17 2014-05-13 The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Vaccinia virus protein A46 peptide and use thereof
HRP20161450T1 (hr) 2008-11-26 2017-01-13 Amgen Inc. Stabilizirana varijanta aktivinskog receptora iib
EP2382235B1 (en) 2008-12-19 2016-02-24 Christiane Hilger Novel caviidae allergen and uses thereof
EP2367564A1 (en) 2008-12-22 2011-09-28 Universität Regensburg Norrin in the treatment of diseases associated with an increased tgf-beta activity
US20100168807A1 (en) * 2008-12-23 2010-07-01 Burton Kevin W Bioactive terpolymer compositions and methods of making and using same
EP2379595A2 (en) 2008-12-23 2011-10-26 AstraZeneca AB Targeted binding agents directed to 5 1 and uses thereof
NZ593892A (en) 2008-12-23 2013-11-29 Biosource Pharm Inc Antibiotic compositions for the treatment of gram negative infections
US20100158978A1 (en) * 2008-12-23 2010-06-24 Peter Markland Bioactive spray coating compositions and methods of making and uses thereof
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
US8974808B2 (en) * 2008-12-23 2015-03-10 Surmodics, Inc. Elastic implantable composites and implants comprising same
US8951546B2 (en) 2008-12-23 2015-02-10 Surmodics Pharmaceuticals, Inc. Flexible implantable composites and implants comprising same
US9415197B2 (en) 2008-12-23 2016-08-16 Surmodics, Inc. Implantable suction cup composites and implants comprising same
WO2010085086A2 (ko) 2009-01-20 2010-07-29 한올바이오파마 주식회사 변형된 인간 트롬보포이에틴 폴리펩타이드 절편 및 그의 제조방법
JP2012515837A (ja) * 2009-01-23 2012-07-12 サーモディクス ファーマシューティカルズ， インコーポレイテッド 異なる非反復単位を有するポリマーを含むポリマー混合物、ならびにそれを作製および使用するための方法
WO2010085609A2 (en) * 2009-01-23 2010-07-29 Surmodics Pharmaceuticals, Inc. Controlled release systems from polymer blends
US20110014190A1 (en) 2009-02-12 2011-01-20 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
JP2012517801A (ja) 2009-02-13 2012-08-09 ノバルティス アーゲー 非リボソームペプチドシンターゼをコードする生合成クラスターの核酸分子およびその使用
TW201031436A (en) * 2009-02-16 2010-09-01 Univ Nat Taiwan Pharmaceutical composition for inhalation delivery and fabrication method thereof
CA2759667A1 (en) 2009-02-18 2010-08-26 Bayer Pharma Aktiengesellschaft Particles comprising drospirenone encapsulated in a polymer
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
PL3248610T3 (pl) 2009-05-05 2024-04-02 Amgen Inc. Mutanty fgf21 i ich zastosowania
CA2760674A1 (en) 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
EP2260857A1 (en) 2009-06-11 2010-12-15 Alfact Innovation Novel applications of HIP/PAP or derivatives thereof
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
IN2012DN00352A (forum.php) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
EP2443145A1 (en) 2009-06-17 2012-04-25 Amgen, Inc Chimeric fgf19 polypeptides and uses thereof
WO2011010132A1 (en) 2009-07-21 2011-01-27 Astrazeneca Ab Sustained-release composition comprising compound 600
WO2011010131A1 (en) 2009-07-21 2011-01-27 Astrazeneca Ab Compositions comprising an oxoisoquinoline methylbenzamide and a polymer
AU2010278067B2 (en) 2009-07-31 2016-10-27 Shin Maeda Cancer metastasis inhibitor
TW201118166A (en) 2009-09-24 2011-06-01 Chugai Pharmaceutical Co Ltd HLA class I-recognizing antibodies
EP2305285A1 (en) 2009-09-29 2011-04-06 Julius-Maximilians-Universität Würzburg Means and methods for treating ischemic conditions
EP2305810A1 (en) 2009-10-02 2011-04-06 Technische Universität München miRNAs in the treatment of fibrosis
EP2308478A1 (en) 2009-10-06 2011-04-13 Abbott GmbH & Co. KG Delivery system for sustained release of a calcium-channel blocking agent
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
CN102711772A (zh) 2009-10-16 2012-10-03 奥克兰联合服务有限公司 Artemin拮抗剂的抗肿瘤用途
EP2492281B1 (en) 2009-10-19 2018-04-11 HanAll Biopharma Co., Ltd. Modified human tumor necrosis factor receptor-1 polypeptide or fragment thereof, and method for preparing same
WO2011050175A1 (en) 2009-10-21 2011-04-28 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
EP2490698A4 (en) 2009-10-22 2013-09-25 Hoffmann La Roche MODULATION OF AXONES DEGENERATION
US8729058B2 (en) 2009-10-27 2014-05-20 Michael Zasloff Methods and compositions for treating and preventing viral infections
CA2779615C (en) 2009-11-02 2023-03-14 University Of Washington Therapeutic nuclease compositions and methods
EP2498803A4 (en) 2009-11-13 2013-05-15 Puget Sound Blood Ct FACTOR VIII CELL EPITOPARIANTS WITH REDUCED IMMUNOGENITY
SMT202000195T1 (it) 2009-11-24 2020-05-08 Medimmune Ltd Agenti leganti direzionati contro b7-h1
US8623416B2 (en) 2009-11-25 2014-01-07 Michael Zasloff Formulations comprising aminosterols
US8491927B2 (en) 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
JP5885668B2 (ja) 2009-12-02 2016-03-15 アダマス ファーマシューティカルズ， インコーポレイテッド アマンタジン組成物および使用方法
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
CA2784800A1 (en) 2009-12-21 2011-07-21 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
EA201290541A1 (ru) 2009-12-21 2013-05-30 Амбркс, Инк. Модифицированные бычьи соматотропиновые полипептиды и их применение
JP5878477B2 (ja) 2010-01-15 2016-03-08 ユニバーシティ オブ メディスン アンド デンティストリー オブ ニュー ジャージー 骨の治癒を加速するためのバナジウム化合物の使用
US20130053438A1 (en) 2010-01-19 2013-02-28 Universitat Innsbruck Pharmaceutical compositions comprising lignans and their derivatives for the medical management of angiogenesis and hypovascularity
WO2011094430A2 (en) 2010-01-27 2011-08-04 Children's Medical Center Corporation Pro-angiogenic fragments of prominin-1 and uses thereof
CN102753575A (zh) 2010-01-28 2012-10-24 诺沃—诺迪斯克保健股份有限公司 因子vii融合多肽
US8778416B2 (en) 2010-02-10 2014-07-15 Nayacure Therapeutics Ltd. Pharmaceutical compositions and methods for the treatment and prevention of cancer
GB201003559D0 (en) 2010-03-03 2010-04-21 Proteo Biotech Ag Novel use of elafin
JP2013525271A (ja) 2010-03-12 2013-06-20 チルドレンズ メディカル センター コーポレーション 免疫原およびそのスクリーニング方法
JPWO2011118804A1 (ja) 2010-03-26 2013-07-04 国立大学法人徳島大学 新規抗ｃｄ９８抗体とその用途
CA2796055A1 (en) 2010-04-15 2011-10-20 Amgen Inc. Human fgf receptor and .beta.-klotho binding proteins
EP2561068A1 (en) 2010-04-19 2013-02-27 Medizinische Universität Innsbruck Tmem195 encodes for tetrahydrobiopterin-dependent alkylglycerol monooxygenase activity
US8993572B2 (en) 2010-04-22 2015-03-31 Intra-Cellular Therapies, Inc. Pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines derivatives and [1,4]oxazino[2,3,4-hi]pyrido[4,3-b]indole derivatives
GB201007531D0 (en) 2010-05-05 2010-06-23 Imp Innovations Ltd Composition
WO2011138457A1 (en) 2010-05-07 2011-11-10 Technische Universität Graz Ucp1 (thermogenin) - inducing agents for use in the treatment of a disorder of the energy homeostasis
US9273316B2 (en) 2010-05-21 2016-03-01 Peptimed, Inc. Reagents and methods for treating cancer
SI2578231T1 (sl) 2010-05-28 2023-01-31 Chugai Seiyaku Kabushiki Kaisha Okrepljen protitumorski T celični odzivnik
US20130149302A1 (en) 2010-05-28 2013-06-13 Chugai Seiyaku Kabushiki Kaisha Therapeutic agents for pancreatic cancer
US20130115237A1 (en) 2010-06-09 2013-05-09 Vaccine Technologies, Incorporated Therapeutic immunization in hiv infected subjects to augment antiretroviral treatment
KR20150039882A (ko) 2010-06-16 2015-04-13 앙도르쉐르슈 인코포레이티드 에스트로겐-관련 질병의 치료 또는 예방 방법
CA2802635A1 (en) 2010-06-18 2011-12-22 Xiberscience Gmbh Peptides as active agents to stabilize biologic barriers
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
EP2585092A1 (en) 2010-06-24 2013-05-01 Torrent Pharmaceuticals Limited Pharmaceutical composition containing goserelin for in-situ implant
US9211175B2 (en) 2010-07-08 2015-12-15 Covidien Lp Self-detachable medical devices
AU2011277983C1 (en) 2010-07-16 2016-09-29 Ablynx Nv Modified single domain antigen binding molecules and uses thereof
FR2962646B1 (fr) 2010-07-16 2012-06-22 Sofradim Production Prothese avec element radio-opaque
UY33517A (es) 2010-07-19 2012-02-29 Astrazeneca Ab Depósito farmacéutico para 5-fluoro-2-[[(1S)-1-(5-fluoro-2-piridil)etil]amino]-6-[(5-isopropoxi-1H-pirazol-3-il)amino]piridin-3-carbonitrilo?.
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
SI3572091T1 (sl) 2010-08-17 2024-07-31 Ambrx, Inc., Modificirani polipeptidi relaksina in njihova uporaba
EP2611868B1 (en) 2010-08-30 2020-01-08 Surmodics Pharmaceuticals, Inc. Biodegradable terpolymers and terpolymer blends as pressure-sensitive adhesives
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
AU2011309114B2 (en) 2010-09-28 2015-03-19 Nb Health Laboratory Co., Ltd. Antihuman CCR7 antibodies, hybridoma, nucleic acid, vector, cell, medicinal composition, and antibody-immobilized carrier
US9572907B2 (en) 2010-10-01 2017-02-21 Covidien Lp Implantable polymeric films
CA2813304A1 (en) 2010-10-01 2012-04-05 Biogen Idec Ma Inc. Interferon-beta for use as monotherapy or in combination with other cancer therapies
US8920867B2 (en) 2010-10-19 2014-12-30 Covidien Lp Methods of forming self-supporting films for delivery of therapeutic agents
US9861590B2 (en) 2010-10-19 2018-01-09 Covidien Lp Self-supporting films for delivery of therapeutic agents
US8632839B2 (en) 2010-10-19 2014-01-21 Covidien Lp Methods of forming self-supporting films for delivery of therapeutic agents
WO2012061120A1 (en) 2010-10-25 2012-05-10 Regents Of The University Of Minnesota Therapeutic composition for treatment of glioblastoma
CA3085710A1 (en) 2010-10-27 2012-05-03 Amgen Inc. Dkk1 antibodies and methods of use
BR112013010911A2 (pt) 2010-11-01 2017-05-02 Peptimed Inc composições de um sistema à base de peptídeo para direcionamento para céllas específicas
BR112013012213A2 (pt) 2010-11-17 2020-09-01 Chugai Seiyaku Kabushiki Kaisha moléculas de ligação a antígeno mul tlespecíficas tendo função alternativa à função dos fatores viii, ix e x de coagulação sanguínea, e anticorpo bies- 5 pecífico, seus usos na prevenção ou tratamento de hemorragia, ácido nucleico, vetor, célula, método para produzir as referidas moléculas de ligação, composição farmacêutica e kit
GB201019467D0 (en) 2010-11-17 2010-12-29 Biotecnol Sa Therapeutic agent
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
MX357166B (es) 2010-11-24 2018-06-28 Lexicon Pharmaceuticals Inc Anticuerpos que se unen a notum pectinacetilesterasa.
JP6278598B2 (ja) 2010-11-30 2018-02-14 中外製薬株式会社 細胞傷害誘導治療剤
PL2657252T3 (pl) 2010-12-23 2017-08-31 Hanall Biopharma Co., Ltd. Modyfikowany polipeptyd ludzkiego receptora-1 czynnika martwicy nowotworu lub jego fragment i sposób ich wytwarzania
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
US9144634B2 (en) 2011-01-14 2015-09-29 Covidien Lp Medical device with intrapore films
EP2668207A4 (en) 2011-01-24 2015-06-10 Univ Singapore MANNOSE-CAPTURED LIPOARABINOMANANE ANTIGEN-BINDING PROTEINS OBTAINED FROM ILLNESSIFYING MYCOBACTERIES
JP6348283B2 (ja) 2011-01-27 2018-06-27 ニューレン ファーマシューティカルズ リミテッド グリシル−ｌ−２−メチルプロリル−ｌ−グルタミン酸を用いる自閉症スペクトラム障害の治療
CA2828000A1 (en) 2011-03-01 2012-09-07 Amgen Inc. Bispecific binding agents
KR20140021594A (ko) 2011-03-10 2014-02-20 제넨테크, 인크. 혈관 장벽 기능이 변경된 장애의 치료
AU2012240231B2 (en) 2011-04-04 2017-05-25 University Of Iowa Research Foundation Methods of improving vaccine immunogenicity
CA2831957A1 (en) 2011-04-07 2012-10-11 Amgen Inc. Novel egfr binding proteins
EP2694092B1 (en) 2011-04-08 2017-01-04 Amgen Inc. Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
US9446135B2 (en) 2011-04-25 2016-09-20 Shandong Luye Pharmaceutical Co., Ltd. Risperidone sustained release microsphere composition
BR112013027547B1 (pt) 2011-04-29 2021-01-19 University Of Washington polipeptídeo, dímero, composição, molécula de ácido nucleico, vetor de expressão recombinante, célula hospedeira microbiana, método para preparar o polipeptídeo e composição contendo nucleasse
WO2012151317A1 (en) 2011-05-03 2012-11-08 Genentech, Inc. Vascular disruption agents and uses thereof
ES2579319T3 (es) 2011-05-04 2016-08-09 Balance Therapeutics, Inc. Derivados de pentilenotetrazol
US20140189893A1 (en) 2011-05-10 2014-07-03 Amgen Inc. Method of identifying compounds that specifically modulate the interaction of fgfr1 and beta klotho
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
RU2619176C2 (ru) 2011-05-11 2017-05-12 Чилдрен'С Медикал Сентер Корпорейшн Иммуногенная композиция презентации множественных антигенов, относящиеся к ней способы и применения
US9574002B2 (en) 2011-06-06 2017-02-21 Amgen Inc. Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
CN103917093B (zh) 2011-06-14 2017-08-11 比卡姆药品公司 视蛋白结合配体、组合物及使用方法
MX2013014847A (es) 2011-06-17 2015-01-12 Amgen Inc Metodo para tratar o aminorar trastornos metabolicos udando clec-2.
FR2977790B1 (fr) 2011-07-13 2013-07-19 Sofradim Production Prothese pour hernie ombilicale
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
US8579924B2 (en) 2011-07-26 2013-11-12 Covidien Lp Implantable devices including a mesh and a pivotable film
WO2013017656A1 (en) 2011-08-02 2013-02-07 Medizinische Universität Wien Antagonists of ribonucleases for treating obesity
US9328386B2 (en) 2011-08-16 2016-05-03 Evotec (München) Gmbh Markers for susceptibility to an inhibitor of an Src-family kinase
EP3348575A1 (en) 2011-08-16 2018-07-18 Emory University Jaml specific binding agents, antibodies, and uses related thereto
WO2013025939A2 (en) 2011-08-16 2013-02-21 Indiana University Research And Technology Corporation Compounds and methods for treating cancer by inhibiting the urokinase receptor
EP2744508B1 (en) 2011-08-19 2017-11-08 Children's Medical Center Corporation Vegf-binding protein for blockade of angiogenesis
US9782957B2 (en) 2011-08-24 2017-10-10 Covidien Lp Medical device films
AU2012301769B2 (en) 2011-08-31 2016-05-19 Amgen Inc. FGF21 for use in treating type 1 diabetes
WO2013039916A1 (en) 2011-09-12 2013-03-21 The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services Compositions for and methods of treatment and enhanced detection of non-pituitary tumors
CN104136461B (zh) 2011-09-22 2021-06-08 安姆根有限公司 Cd27l抗原结合蛋白
US9458214B2 (en) 2011-09-26 2016-10-04 Novartis Ag Dual function fibroblast growth factor 21 proteins
JO3476B1 (ar) 2011-09-26 2020-07-05 Novartis Ag بروتينات مندمجة لعلاج الاضطرابات الايضية
HK1198813A1 (en) 2011-09-30 2015-06-12 中外制药株式会社 Antigen-binding molecule inducing immune response to target antigen
DE102011114864A1 (de) 2011-10-05 2013-04-11 Acino Ag Verfahren zur Herstellung einer homogenen Pulvermischung und Verfahren zur Herstellung eines Implantats sowie Implantat
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
US8906860B2 (en) 2011-10-14 2014-12-09 The Board Of Trustees Of The University Of Illinois Methods and compositions inhibiting tumor cell proliferation
US20130172265A1 (en) 2011-10-14 2013-07-04 The Board Of Trustees Of The University Of Illinois Methods and Compositions for Inhibiting Tumor Cell Proliferation
US9499464B2 (en) 2011-10-19 2016-11-22 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
US9179994B2 (en) 2011-10-25 2015-11-10 Covidien Lp Implantable film/mesh composite
US9005308B2 (en) 2011-10-25 2015-04-14 Covidien Lp Implantable film/mesh composite for passage of tissue therebetween
US8932621B2 (en) 2011-10-25 2015-01-13 Covidien Lp Implantable film/mesh composite
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
CN104168922A (zh) 2011-11-16 2014-11-26 安姆根有限公司 治疗表皮生长因子缺失突变体viii相关疾病的方法
GR1007832B (el) 2011-11-21 2013-02-14 Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη"
ES3018133T3 (en) 2011-11-30 2025-05-14 Univ Emory Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae
AU2012346214B2 (en) 2011-11-30 2017-09-14 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
US10040749B2 (en) 2011-12-01 2018-08-07 Bikam Pharmaceuticals Inc. Opsin-binding ligands, compositions and methods of use
AU2012347540A1 (en) 2011-12-08 2014-06-26 Amgen Inc. Agonistic human LCAT antigen binding proteins and their use in therapy
WO2013083810A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
SG10201605027XA (en) 2011-12-19 2016-08-30 Amgen Inc Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
WO2013096516A1 (en) 2011-12-19 2013-06-27 Xoma Technology Ltd. Methods for treating acne
EP3560509B1 (en) 2011-12-22 2024-01-31 Children's Medical Center Corporation Saposin-a derived peptides and uses thereof
CA2863224A1 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
EP3663314A1 (en) 2012-01-09 2020-06-10 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
JP2015504674A (ja) 2012-01-11 2015-02-16 アリゾナ ボード オブ リージェンツ ア ボディ コーポレート オブ ザ ステイト オブ アリゾナ アクティング フォー アンド オン ビハーフ オブ アリゾナ ステイト ユニバーシティーＡｒｉｚｏｎａ Ｂｏａｒｄ Ｏｆ Ｒｅｇｅｎｔｓ， Ａ Ｂｏｄｙ Ｃｏｒｐｏｒａｔｅ Ｏｆ Ｔｈｅ Ｓｔａｔｅ Ｏｆ Ａｒｉｚｏｎａ Ａｃｔｉｎｇ Ｆｏｒ Ａｎｄ Ｏｎ Ｂｅｈａｌｆ Ｏｆ Ａｒｉｚｏｎａ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ 神経疾患タンパク質の二重特異性抗体フラグメントおよび使用方法
CN104204218A (zh) 2012-01-26 2014-12-10 安姆根有限公司 生长分化因子15 (gdf-15)多肽
EP2626066A1 (en) 2012-02-10 2013-08-14 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Combination therapy comprising selective VEGFR-2 inhibitors and MEK inhibitors
JP6216766B2 (ja) 2012-03-29 2017-10-18 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ クリック核酸
US10206769B2 (en) 2012-03-30 2019-02-19 Covidien Lp Implantable devices including a film providing folding characteristics
US8753643B1 (en) 2012-04-11 2014-06-17 Life-Science Innovations, Llc Spray dried compositions and methods of use
JP6334511B2 (ja) 2012-04-14 2018-05-30 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規方法
CN104379741B (zh) 2012-04-23 2021-07-20 基因先端领域株式会社 抗人cd69抗体及其用于医疗目的的用途
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
EA030716B1 (ru) 2012-05-14 2018-09-28 Байоджен Ма Инк. Антагонисты lingo-2 для лечения заболеваний, в которых участвуют двигательные нейроны
UY34813A (es) 2012-05-18 2013-11-29 Amgen Inc Proteínas de unión a antígeno dirigidas contra el receptor st2
US9844582B2 (en) 2012-05-22 2017-12-19 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
FR2992662B1 (fr) 2012-06-28 2014-08-08 Sofradim Production Tricot avec picots
FR2992547B1 (fr) 2012-06-29 2015-04-24 Sofradim Production Prothese pour hernie
AU2013285537B2 (en) 2012-07-02 2017-10-12 Medizinische Universitat Wien Complement split product C4d for the treatment of inflammatory conditions
EP2687225A1 (en) 2012-07-19 2014-01-22 Alfact Innovation HIP/PAP protein and derivatives thereof for use in treating cancer
CA2879982C (en) 2012-07-25 2020-09-01 Sarcode Bioscience Inc. Lfa-1 inhibitor and polymorph thereof
DE102013011399A1 (de) 2012-07-31 2014-02-06 Amw Gmbh Implantat mit Risperidon
EP2695950A1 (en) 2012-08-10 2014-02-12 Blackfield AG Markers for responsiveness to an inhibitor of the fibroblast growth factor receptor
EP2887942A4 (en) 2012-08-21 2016-08-31 Genesys Res Inst COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING ANTHRACYCLIN-INDUCED CARDIOTOXICITY
EA034163B1 (ru) 2012-10-17 2020-01-13 Васкьюлар Байодженикс Лтд. Конструкция нуклеиновой кислоты, содержащая промотор, специфичный для эндотелиальных клеток, и их противоопухолевое применение
US9309318B2 (en) 2012-10-17 2016-04-12 Amgen, Inc. Compositions relating to anti-IL-21 receptor antibodies
AU2013342779B2 (en) 2012-11-09 2019-09-26 Genefrontier Corporation Anti-ADAM28 antibody for treating cancer
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
CA2889298C (en) 2012-11-30 2024-01-02 Anton Belousov Identification of patients in need of pd-l1 inhibitor cotherapy
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
EP2934588A4 (en) 2012-12-20 2016-09-28 Medimmune Llc LIQUID ANTIBODY FORMULATION HAVING ENHANCED AGGREGATION PROPERTIES
US9920121B2 (en) 2013-01-25 2018-03-20 Amgen Inc. Antibodies targeting CDH19 for melanoma
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
CA2899889A1 (en) 2013-02-01 2014-08-07 Santa Maria Biotherapeutics, Inc. Administration of an anti-activin-a compound to a subject
US11576958B2 (en) 2013-02-07 2023-02-14 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
JP6499591B2 (ja) 2013-02-25 2019-04-10 シナジー ファーマシューティカルズ インコーポレイテッド 結腸洗浄において用いるためのグアニル酸シクラーゼ受容体アゴニスト
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
JP2016512523A (ja) 2013-03-11 2016-04-28 デュレクト コーポレーション 高粘性液体キャリアを含む注射用制御放出組成物
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
US9546203B2 (en) 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
CA2904337A1 (en) 2013-03-14 2014-10-02 Amgen Inc. Chrdl-1 antigen binding proteins and methods of treatment
US9850297B2 (en) 2013-03-15 2017-12-26 Amgen Inc. Secreted frizzle-related protein 5 (SFRP5) binding proteins
SG11201507416WA (en) 2013-03-15 2015-10-29 Amgen Inc Human pac1 antibodies
CA2904722C (en) 2013-03-15 2023-01-03 Amgen Inc. Methods and compositions relating to anti-ccr7 antigen binding proteins
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
PT2970449T (pt) 2013-03-15 2019-11-06 Amgen Res Munich Gmbh Moléculas de ligação de cadeia única compreendendo abp n-terminal
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
TW201521769A (zh) 2013-03-15 2015-06-16 Durect Corp 具有流變改質劑以減少溶解變異性之組成物
PT2968320T (pt) 2013-03-15 2021-01-28 Intra Cellular Therapies Inc Compostos orgânicos
EP2970446A1 (en) 2013-03-15 2016-01-20 Amgen Research (Munich) GmbH Antibody constructs for influenza m2 and cd3
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP2968480B1 (en) 2013-03-15 2020-10-14 Amgen Inc. Treating metabolic disorders using pla2g12a polypeptides and pla2g12a mutant polypeptides
ES2716384T3 (es) * 2013-04-18 2019-06-12 Shandong luye pharmaceutical co ltd Composición farmacéutica de microesferas de liberación sostenida de goserelina
US10501803B2 (en) 2013-05-21 2019-12-10 Max-Planck Gesellschaft zur Förderung der Wissenschaften e.V. Isoforms of GATA6 and NKX2-1 as markers for diagnosis and therapy of cancer and as targets for anti-cancer therapy
AU2014270882B2 (en) 2013-05-22 2019-03-14 Zensun (Shanghai) Science & Technology, Co. Ltd. Extended release of neuregulin for treating heart failure
WO2014193800A2 (en) 2013-05-28 2014-12-04 The Johns Hopkins University Aptamers for the treatment of sickle cell disease
CN107513105B (zh) 2013-05-30 2019-08-16 基尼克萨制药有限公司 制瘤素m受体抗原结合蛋白
EP2810648A1 (en) 2013-06-04 2014-12-10 Daniel Rauh Targeting domain-domain interaction for the identification of kinase modulators
EP3009518B1 (en) 2013-06-11 2020-08-12 National Center of Neurology and Psychiatry Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (rrms) patient, and method for determining applicability of novel therapy
AU2014280847B2 (en) 2013-06-13 2019-07-04 Antisense Therapeutics Ltd Combination therapy
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
EP2835135A3 (en) 2013-06-19 2015-06-24 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin Means and methods for treating pseudomonas infection
WO2014209384A1 (en) 2013-06-28 2014-12-31 Amgen Inc. Methods for treating homozygous familial hypercholesterolema
WO2015017146A2 (en) 2013-07-18 2015-02-05 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
AU2014290361B2 (en) 2013-07-18 2019-04-18 Taurus Biosciences, Llc Humanized antibodies with ultralong complementarity determining regions
CA2918624C (en) 2013-07-31 2024-02-13 Amgen Inc. Growth differentiation factor 15 (gdf-15) constructs
WO2015022326A1 (en) 2013-08-12 2015-02-19 Xiber Science Gmbh Peptides as active agents for treating primary graft dysfunction
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
AU2014318017B2 (en) 2013-09-05 2020-02-06 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
EP3043790B1 (en) 2013-09-11 2021-05-26 The Administrators of the Tulane Educational Fund Novel anthranilic amides and the use thereof
CN105792851B (zh) 2013-09-13 2023-10-10 斯克利普斯研究所 修饰的治疗剂及其组合物
TWI688401B (zh) 2013-09-13 2020-03-21 美商安進公司 用於治療骨髓性白血病的表觀遺傳因子與靶向ｃｄ３３及ｃｄ３之雙特異性化合物的組合
EP3339318A1 (en) 2013-09-16 2018-06-27 CeMM - Forschungszentrum für Molekulare Medizin GmbH Mutant calreticulin for the diagnosis of myeloid malignancies
US20160229922A1 (en) 2013-09-20 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Treatment for hemorrhagic diseases by anti-protein-c antibody
GB201316738D0 (en) 2013-09-20 2013-11-06 Rainbow Medical Engineering Ltd Implantable Medical Devices
WO2015048331A1 (en) 2013-09-25 2015-04-02 Cornell University Compounds for inducing anti-tumor immunity and methods thereof
KR20160058960A (ko) 2013-10-04 2016-05-25 압토스 바이오사이언시스 인코포레이티드 암을 치료하기 위한 조성물과 방법
CN106061494A (zh) 2013-10-10 2016-10-26 辛纳吉制药公司 可用于治疗阿片样物质诱导的功能障碍的鸟苷酸环化酶的激动剂
CA2927525C (en) 2013-10-15 2023-01-31 Genefrontier Corporation Human antibody against aggrecanase-type adamts species for therapeutics of aggrecanase-related diseases
CN105829349B (zh) 2013-10-15 2023-02-03 斯克利普斯研究所 肽嵌合抗原受体t细胞开关和其用途
US20150238631A1 (en) 2013-10-15 2015-08-27 The California Institute For Biomedical Research Chimeric antigen receptor t cell switches and uses thereof
EP3057605A1 (en) 2013-10-18 2016-08-24 Novartis AG Methods of treating diabetes and related disorders
CN106170491B (zh) 2013-10-30 2020-07-24 阿尔杰妮卡治疗学有限公司 神经保护肽
PL3063275T3 (pl) 2013-10-31 2020-03-31 Resolve Therapeutics, Llc Terapeutyczne fuzje nukleaza-albumina i sposoby
GB201319374D0 (en) 2013-11-01 2013-12-18 Univ Nottingham Glycans as functional cancer targets abd antibodies thereto
JP6475727B2 (ja) 2013-12-03 2019-02-27 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規方法
CN106456589B (zh) 2013-12-18 2020-07-07 斯克利普斯研究所 修饰的治疗剂、订合的肽脂质缀合物及其组合物
CN103965357B (zh) 2013-12-31 2016-08-17 嘉和生物药业有限公司 一种抗人rankl抗体
WO2015110930A1 (en) 2014-01-24 2015-07-30 Pfizer Inc. Modified interleukin 21 receptor proteins
WO2015120187A1 (en) 2014-02-05 2015-08-13 The University Of Chicago Chimeric antigen receptors recognizing cancer-spevific tn glycopeptide variants
US10532083B2 (en) 2014-02-13 2020-01-14 Technische Universität München Methods for inducing differentiation or conversion of white adipocytes and/or preadipocytes to brown adipocites using FGF8
WO2015127134A2 (en) 2014-02-20 2015-08-27 Allergan, Inc. Complement component c5 antibodies
KR20160126054A (ko) 2014-02-27 2016-11-01 알러간, 인코포레이티드 보체 인자 Bb 항체
AU2015226881A1 (en) 2014-03-07 2016-09-29 Intonation Research Laboratories Inhibitors of histone lysine specific demethylase (LSD1) and histone deacetylases (HDACs)
US10472334B2 (en) 2014-03-14 2019-11-12 The University Of North Carolina At Chapel Hill Small molecules for inhibiting male fertility
MX2021014508A (es) 2014-04-04 2023-05-18 Intra Cellular Therapies Inc Gamma-carbolinas fusionadas con heterociclos sustituidas con deuterio.
US9745300B2 (en) 2014-04-04 2017-08-29 Intra-Cellular Therapies, Inc. Organic compounds
US10507227B2 (en) 2014-04-15 2019-12-17 The Hospital For Sick Children Cationic antimicrobial peptides
WO2015158823A1 (de) 2014-04-16 2015-10-22 Veyx-Pharma Gmbh Veterinärpharmazeutische zusammensetzung und deren verwendung
WO2015173398A1 (en) 2014-05-15 2015-11-19 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Antagonists of slc38a9 and their use in therapy
US20170119851A1 (en) 2014-05-19 2017-05-04 Novartis Ag Methods of treating anorexia
WO2015184260A2 (en) 2014-05-30 2015-12-03 The Johns Hopkins University Methods for treating mendelian disorders of the epigenetic machinery
MY191346A (en) 2014-06-03 2022-06-17 Xbiotech Inc Compositions and methods for treating and preventing staphylococcus aureus infections
US10179776B2 (en) 2014-06-09 2019-01-15 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
KR20240093956A (ko) 2014-06-09 2024-06-24 울트라제닉스 파마수티컬 인코포레이티드 최적의 골 형성을 위한 혈청 포스페이트의 효과적이고 효율적인 조절
JP2017519009A (ja) 2014-06-13 2017-07-13 サンタ マリア バイオセラピューティクス インコーポレイテッド 製剤化された受容体ポリペプチドおよび関連する方法
TWI831106B (zh) 2014-06-20 2024-02-01 日商中外製藥股份有限公司 用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物
WO2016007919A2 (en) 2014-07-11 2016-01-14 Regents Of The University Of Minnesota Antibody fragments for detecting cancer and methods of use
EP2977758A1 (en) 2014-07-24 2016-01-27 Université De Nice Sophia Antipolis Methods and kits for monitoring membranous nephropathy
ES2743809T3 (es) 2014-07-31 2020-02-20 Amgen Res Munich Gmbh Constructos de anticuerpo monocatenarios biespecificos específicos de especies cruzadas optimizados
UY36245A (es) 2014-07-31 2016-01-29 Amgen Res Munich Gmbh Constructos de anticuerpos para cdh19 y cd3
WO2016025647A1 (en) 2014-08-12 2016-02-18 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
CA3133162C (en) 2014-08-12 2024-02-13 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
CN107109410B (zh) 2014-08-22 2021-11-02 奥克兰联合服务有限公司 通道调节剂
EP3186378A1 (en) 2014-08-27 2017-07-05 Peptimed, Inc. Anti-tumor compositions and methods
WO2016040767A2 (en) 2014-09-12 2016-03-17 Amgen Inc. Chrdl-1 epitopes and antibodies
TWI683667B (zh) 2014-10-21 2020-02-01 開曼群島商賽生製藥國際有限公司 用免疫刺激物治療癌症
PT3412302T (pt) 2014-10-24 2021-06-09 Bristol Myers Squibb Co Polipéptidos de fgf-21 modificados e utilizações dos mesmos
WO2016069889A1 (en) 2014-10-31 2016-05-06 Resolve Therapeutics, Llc Therapeutic nuclease-transferrin fusions and methods
WO2016079321A1 (en) 2014-11-20 2016-05-26 Cemm Forschungszentrum Für Molekulare Medizin Gmbh Antagonists of setdb2 for use in the therapy of infectious diseases
EP3085709B1 (en) 2014-12-28 2019-08-21 Genor Biopharma Co., Ltd Humanized anti-human rankl antibody, pharmaceutical composition and use thereof
HK1246810A1 (zh) 2015-01-08 2018-09-14 Biogen Ma Inc. Lingo-1对抗药及用於治疗脱髓鞘疾病的用途
US20180170992A1 (en) 2015-01-26 2018-06-21 The University Of Chicago CAR T CELLS RECOGNIZING CANCER-SPECIFIC IL 13Ra2
US10308719B2 (en) 2015-01-26 2019-06-04 The University Of Chicago IL13Rα2 binding agents and use thereof in cancer treatment
US9744239B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
CN107810192A (zh) 2015-02-23 2018-03-16 海鸥治疗简易股份公司 非天然的脑信号蛋白3及其医药用途
US10800828B2 (en) 2015-03-26 2020-10-13 The Scripps Research Institute Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
UA126270C2 (uk) 2015-04-10 2022-09-14 Емджен Інк. Мутеїни інтерлейкіну-2 для росту регуляторних t-клітин
EP3283113A4 (en) 2015-04-15 2018-12-05 The California Institute for Biomedical Research Optimized pne-based chimeric receptor t cell switches and uses thereof
IL255076B2 (en) 2015-04-17 2023-10-01 Amgen Res Munich Gmbh Bispecific antibody constructs for cdh3 and cd3
US20180146703A1 (en) * 2015-05-15 2018-05-31 The Johns Hopkins University Novel fluoride prenatal dietary supplement
US20160361380A1 (en) 2015-06-12 2016-12-15 Nymox Corporation Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
WO2016205488A1 (en) 2015-06-17 2016-12-22 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
US10676490B2 (en) 2015-07-07 2020-06-09 Florida Southwestern State College Use of amine carboxyboranes as therapeutic delivery of carbon monoxide and as general drug delivery system in the presence of reactive oxygen species
ES2546566B2 (es) 2015-07-23 2016-09-14 Universidade De Santiago De Compostela Sistema para la administración de sustancias biológicamente activas preparado por técnicas de espumado empleando gases comprimidos o fluidos supercríticos
TWI793062B (zh) 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
US10842763B2 (en) 2015-07-31 2020-11-24 The Johns Hopkins University Methods for cancer and immunotherapy using prodrugs of glutamine analogs
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
CN108290827B (zh) 2015-07-31 2021-01-01 约翰霍普金斯大学 谷氨酰胺类似物的前药
EP3328374A4 (en) 2015-07-31 2019-03-13 The Johns Hopkins University GLUTAMINANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITES
WO2017023787A1 (en) 2015-07-31 2017-02-09 The Johns Hopkins University Methods and compositions for treating metabolic reprogramming disorders
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
JO3620B1 (ar) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
JP2018529729A (ja) 2015-10-01 2018-10-11 アムジエン・インコーポレーテツド 胆汁酸障害の処置
US10888609B2 (en) 2015-11-03 2021-01-12 Regents Of The University Of Minnesota CD200 inhibitors and methods of use thereof
EP3370771A4 (en) 2015-11-03 2019-06-19 Ambrx, Inc. ANTI-CD3-FOLATE CONJUGATES AND USES THEREOF
CA3002880A1 (en) 2015-11-03 2017-05-11 Glycomimetics, Inc. Methods and compositions for the production of monoclonal antibodies, hematopoietic stem cells, and methods of using the same
WO2017086419A1 (ja) 2015-11-18 2017-05-26 中外製薬株式会社 液性免疫応答の増強方法
WO2017086367A1 (ja) 2015-11-18 2017-05-26 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
US20170157215A1 (en) 2015-12-04 2017-06-08 Jomoco, Corp. Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
CN108778320A (zh) 2015-12-18 2018-11-09 泰伦基国际有限公司 一种预防和治疗心血管病的新方法
US10294303B2 (en) 2015-12-23 2019-05-21 Amgen Inc. Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists
WO2017110980A1 (ja) 2015-12-25 2017-06-29 中外製薬株式会社 増強された活性を有する抗体及びその改変方法
US10653744B2 (en) 2016-01-11 2020-05-19 Bausch Health Ireland Limited Formulations and methods for treating ulcerative colitis
JOP20170017B1 (ar) 2016-01-25 2021-08-17 Amgen Res Munich Gmbh تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص
PL3838274T3 (pl) 2016-01-26 2024-04-02 Intra-Cellular Therapies, Inc. Pochodna pirydo[3',4':4,5]pirolo[1,2,3-DE]chinoksaliny do zastosowania w leczeniu zaburzeń OUN
CN109311979A (zh) 2016-02-03 2019-02-05 安进研发（慕尼黑）股份有限公司 Psma和cd3双特异性t细胞接合抗体构建体
SI3411402T1 (sl) 2016-02-03 2022-03-31 Amgen Research (Munich) Gmbh Konstrukti bispecifičnih protiteles BCMA in CD3, ki aktivirajo T celico
EA039859B1 (ru) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
US10098909B2 (en) 2016-02-05 2018-10-16 University Of South Florida Ionic cocrystal of lithium, lispro, for the treatment of fragile X syndrome
JP2019506412A (ja) 2016-02-10 2019-03-07 ラトガース， ザ ステイト ユニバーシティー オブ ニュージャージー 結核菌（Ｍｙｃｏｂａｃｔｅｒｉｕｍ Ｔｕｂｅｒｃｕｌｏｓｉｓ）感染の診断および治療のための新規な抗−ＬＡＭおよび抗−ＰＩＭ６／ＬＡＭモノクローナル抗体
EP3216458A1 (en) 2016-03-07 2017-09-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Modified vascular endothelial growth factor a (vegf-a) and its medical use
TW202342540A (zh) 2016-03-14 2023-11-01 日商中外製藥股份有限公司 用於癌之治療的細胞傷害誘導治療劑
IL281050B2 (en) 2016-03-25 2023-04-01 Intra Cellular Therapies Inc A controlled or delayed release pharmaceutical preparation containing a deuterated compound
EP3436083A4 (en) 2016-03-28 2019-11-27 Intra-Cellular Therapies, Inc. NOVEL COMPOSITIONS AND METHOD
EP3808764A1 (en) 2016-05-04 2021-04-21 Amgen Inc. Interleukin-2 muteins for the expansion of t-regulatory cells
US10183058B2 (en) 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
US20190241878A1 (en) 2016-07-01 2019-08-08 Resolve Therapeutics, Llc Optimized binuclease fusions and methods
CA3028450A1 (en) 2016-07-06 2018-01-11 Durect Corporation Oral dosage form with drug composition, barrier layer and drug layer
WO2018013924A1 (en) 2016-07-15 2018-01-18 Massachusetts Institute Of Technology Synthetic nanoparticles for delivery of immunomodulatory compounds
US10172910B2 (en) 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
WO2018031454A1 (en) 2016-08-08 2018-02-15 Amgen Inc. Method of improving connective tissue attachment using anti-sclerostin antibodies
US10981976B2 (en) 2016-08-31 2021-04-20 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof
AU2017325240B9 (en) 2016-09-06 2025-02-13 Chugai Seiyaku Kabushiki Kaisha Methods of using a bispecific antibody that recognizes coagulation factor IX and/or activated coagulation factor IX and coagulation factor X and/or activated coagulation factor X
US10532081B2 (en) 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
ES2875329T3 (es) 2016-09-16 2021-11-10 Res Triangle Inst Antagonistas de opioides kappa de tetrahidroisoquinolina
CN110072518B (zh) 2016-10-12 2021-10-26 细胞内治疗公司 无定形固体分散体
ES3030503T3 (en) 2016-10-19 2025-06-30 Scripps Research Inst Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
TW201829448A (zh) 2016-12-15 2018-08-16 大陸商深圳瑞健生命科學硏究院有限公司 纖溶酶原在製備預防或治療肥胖症及疾病倂發的肥胖的藥物中的用途
EP3556381A4 (en) 2016-12-15 2020-09-23 Talengen International Limited MEDICINAL PRODUCT FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS AND ITS USES
WO2018107695A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种预防和治疗肾纤维化的方法
US11389515B2 (en) 2016-12-15 2022-07-19 Talengen International Limited Method for mitigating heart disease
TWI763680B (zh) 2016-12-15 2022-05-11 大陸商深圳瑞健生命科學硏究院有限公司 纖溶酶原在製備藥物中的用途
CA3046669A1 (en) 2016-12-15 2018-06-21 Talengen International Limited Method for preventing and treating skin fibrosis
US20190328850A1 (en) 2016-12-15 2019-10-31 Talengen International Limited Method for preventing and treating lipid metabolism disorders and related diseases thereof
WO2018126143A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
US10961245B2 (en) 2016-12-29 2021-03-30 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines for treatment of central nervous system disorders
JP6908709B2 (ja) 2017-01-06 2021-07-28 エービーエル バイオ インコーポレイテッド 抗α−ｓｙｎ抗体およびその使用
CA3049110A1 (en) 2017-01-06 2018-07-12 Abl Bio Inc. Anti-.alpha.-syn antibody and use thereof
US11529391B2 (en) 2017-01-09 2022-12-20 The Board Of Trustees Of The Leland Stanford Junior University Reversing deficient hedgehog signaling restores deficient skeletal regeneration
WO2018132516A1 (en) 2017-01-10 2018-07-19 Nodus Therapeutics Combination tumor treatment with an integrin-binding-fc fusion protein and immune modulator
US10350266B2 (en) 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein
US20190328792A1 (en) 2017-01-11 2019-10-31 Paracelsus Medizinische Privatuniversität Salzburg - Privatstiftung Mesenchymal stem cell-derived extracellular vesicles and their medical use
JOP20190177A1 (ar) 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
JOP20190189A1 (ar) 2017-02-02 2019-08-01 Amgen Res Munich Gmbh تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
AU2018219283B2 (en) 2017-02-08 2022-05-19 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
US10335453B2 (en) 2017-03-01 2019-07-02 Nymox Corporation Compositions and methods for improving sexual function
WO2018160791A1 (en) 2017-03-03 2018-09-07 Massachusetts Institute Of Technology Antimicrobial constructs and uses thereof
US10421968B2 (en) 2017-03-15 2019-09-24 Versitech Limited Amphiphilic dendrimers complexed with siRNA for treatment of cancer
CN116327770A (zh) 2017-03-24 2023-06-27 细胞内治疗公司 新组合物和方法
CN110691973B (zh) 2017-04-25 2024-11-29 普罗瑟拉生物公司 用于定量间α抑制剂蛋白的方法
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
SG11201910183SA (en) 2017-05-04 2019-11-28 Helsingin Yliopisto C-terminal cdnf and manf fragments, pharmaceutical compositions comprising same and uses thereof
US11918650B2 (en) 2017-05-05 2024-03-05 Amgen Inc. Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
ES3035044T3 (en) 2017-05-12 2025-08-27 Max Planck Gesellschaft Phenyl-heterocycle-phenyl derivatives for use in the treatment or prevention of melanoma
JOP20190259A1 (ar) 2017-05-31 2019-10-31 Amgen Inc بروتينات ربط مولد ضد مضادة لـ jagged1
US20190062428A1 (en) 2017-06-19 2019-02-28 Surface Oncology, Inc. Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof
WO2018233604A1 (zh) 2017-06-19 2018-12-27 泰伦基国际有限公司 一种调控glp-1/glp-1r的方法和药物
US20210087286A1 (en) 2017-06-20 2021-03-25 Amgen Inc. Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
AU2018301393B2 (en) 2017-07-11 2025-02-27 Compass Therapeutics Llc Agonist antibodies that bind human CD137 and uses thereof
CA3070089A1 (en) 2017-07-19 2019-01-24 Auckland Uniservices Limited Cytokine modulation
CN111093665A (zh) 2017-07-26 2020-05-01 细胞内治疗公司 有机化合物
US11427587B2 (en) 2017-07-26 2022-08-30 Intra-Cellular Therapies, Inc. Organic compounds
WO2019032827A1 (en) 2017-08-09 2019-02-14 Massachusetts Institute Of Technology PEPTIDE ALBUMIN BINDING CONJUGATES AND METHODS THEREOF
EP3684811A2 (en) 2017-08-17 2020-07-29 Massachusetts Institute of Technology Multiple specificity binders of cxc chemokines and uses thereof
EP3672986A1 (en) 2017-08-22 2020-07-01 Sanabio, LLC Soluble interferon receptors and uses thereof
CA3076337A1 (en) 2017-09-19 2019-03-28 Massachusetts Institute Of Technology Compositions for chimeric antigen receptor t cell therapy and uses thereof
CA3076630A1 (en) 2017-10-04 2019-04-11 Amgen Inc. Transthyretin immunoglobulin fusions
WO2019078344A1 (ja) 2017-10-20 2019-04-25 学校法人兵庫医科大学 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
MA50536A (fr) 2017-10-30 2020-09-09 Enterin Inc Nouvelles formes solides de squalamine et procédés pour les produire
US11718679B2 (en) 2017-10-31 2023-08-08 Compass Therapeutics Llc CD137 antibodies and PD-1 antagonists and uses thereof
WO2019100052A2 (en) 2017-11-20 2019-05-23 Compass Therapeutics Llc Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
EA202091422A1 (ru) 2017-12-11 2020-08-28 Эмджен Инк. Способ непрерывного производства продуктов на основе биспецифических антител
EP4403218A3 (en) 2017-12-14 2024-11-06 ABL Bio, Inc. Bispecific antibody to a-syn/igf1r and use thereof
CA3123318A1 (en) 2017-12-15 2019-06-20 Talengen International Limited Method and drug for preventing or treating osteoarthritis
WO2019126371A1 (en) 2017-12-19 2019-06-27 Massachusetts Institute Of Technology Antigen-adjuvant coupling reagents and methods of use
WO2019131988A1 (en) 2017-12-28 2019-07-04 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
TW201940518A (zh) 2017-12-29 2019-10-16 美商安進公司 針對ｍｕｃ１７和ｃｄ３之雙特異性抗體構建體
TWI822728B (zh) 2018-01-31 2023-11-21 加藤元一 含有il-6抑制劑的哮喘治療劑
EP3749353B1 (en) 2018-02-09 2025-07-30 Galderma Holding SA Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation
JP7037218B2 (ja) 2018-03-14 2022-03-16 サーフィス オンコロジー インコーポレイテッド Ｃｄ３９と結合する抗体及びその使用
US11980617B2 (en) 2018-03-16 2024-05-14 Intra-Cellular Therapies, Inc. Methods of treating acute depression and/or acute anxiety
US11332524B2 (en) 2018-03-22 2022-05-17 Surface Oncology, Inc. Anti-IL-27 antibodies and uses thereof
IL277509B2 (en) 2018-03-23 2023-11-01 Intra Cellular Therapies Inc Organic compounds
BR112020019119A2 (pt) 2018-03-23 2021-01-12 Intra-Cellular Therapies, Inc. Compostos orgânicos
SG11202009341TA (en) 2018-03-29 2020-10-29 Helsingin Yliopisto C-terminal cdnf fragments, pharmaceutical compositions comprising same and uses thereof
BR112020020080A2 (pt) 2018-03-30 2021-01-05 Amgen Inc Variantes de anticorpos c-terminais
AU2019253462B2 (en) 2018-04-09 2025-04-24 Amgen Inc. Growth differentiation factor 15 fusion proteins
WO2019200357A1 (en) 2018-04-12 2019-10-17 Surface Oncology, Inc. Biomarker for cd47 targeting therapeutics and uses therefor
WO2019204743A1 (en) 2018-04-19 2019-10-24 Checkmate Pharmaceuticals, Inc. Synthetic rig-i-like receptor agonists
WO2019207051A1 (en) 2018-04-25 2019-10-31 Università Degli Studi Di Torino Medical use of combinations of non-natural semaphorins 3 and antimetabolites
JP2021525243A (ja) 2018-05-21 2021-09-24 コンパス セラピューティクス リミテッド ライアビリティ カンパニー Ｎｋ細胞による標的細胞の殺傷を増進するための組成物および方法
WO2019226658A1 (en) 2018-05-21 2019-11-28 Compass Therapeutics Llc Multispecific antigen-binding compositions and methods of use
WO2019225777A1 (ko) 2018-05-23 2019-11-28 에이비엘바이오 주식회사 항-ror1 항체 및 그 용도
WO2019225787A1 (ko) 2018-05-24 2019-11-28 에이비엘바이오 주식회사 항-b7-h3 항체 및 그 용도
ES3028377T3 (en) 2018-06-08 2025-06-19 Intra Cellular Therapies Inc Fused gamma-carbolines for acute treatment of anxiety or depression
WO2019241278A1 (en) 2018-06-11 2019-12-19 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines synthesis
AU2019284362A1 (en) 2018-06-11 2021-01-07 University Of Florida Research Foundation, Inc. Materials and methods for treating stress-related disorders and cancer
WO2020011938A1 (en) 2018-07-11 2020-01-16 Medizinische Universität Wien Glucocorticoids for the topical treatment of autoimmune gastritis
WO2020018715A1 (en) 2018-07-17 2020-01-23 Massachusetts Institute Of Technology Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
EP3833443A1 (en) 2018-08-09 2021-06-16 Compass Therapeutics LLC Antigen binding agents that bind cd277 and uses thereof
WO2020033925A2 (en) 2018-08-09 2020-02-13 Compass Therapeutics Llc Antibodies that bind cd277 and uses thereof
EP3833442A2 (en) 2018-08-09 2021-06-16 Compass Therapeutics LLC Antibodies that bind cd277 and uses thereof
CA3110647A1 (en) 2018-08-28 2020-03-05 Ambrx, Inc. Anti-cd3 antibody folate bioconjugates and their uses
WO2020047241A1 (en) 2018-08-29 2020-03-05 Intra-Cellular Therapies, Inc. Novel compositions and methods
BR112021003838A2 (pt) 2018-08-31 2021-05-18 Intra-Cellular Therapies, Inc. métodos novos
KR20210052471A (ko) 2018-08-31 2021-05-10 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
HRP20240016T1 (hr) 2018-09-11 2024-03-29 Ambrx, Inc. Konjugati polipeptida interleukina-2 i njihove uporabe
WO2020053808A1 (en) 2018-09-12 2020-03-19 Georg Dewald Method of diagnosing vasoregulatory disorders
AU2019346335B2 (en) 2018-09-28 2024-07-25 Massachusetts Institute Of Technology Collagen-localized immunomodulatory molecules and methods thereof
CA3114802A1 (en) 2018-10-11 2020-04-16 Amgen Inc. Downstream processing of bispecific antibody constructs
CN113366015A (zh) 2018-10-19 2021-09-07 Ambrx公司 白细胞介素-10多肽缀合物、其二聚体及其用途
CN113544151B (zh) 2018-12-13 2025-03-14 表面肿瘤学有限责任公司 抗il-27抗体及其用途
AU2019403150B2 (en) 2018-12-17 2025-04-24 Intra-Cellular Therapies, Inc. Organic compound
EP3906062A1 (en) 2019-01-04 2021-11-10 Resolve Therapeutics, LLC Treatment of sjogren's disease with nuclease fusion proteins
US11680105B2 (en) 2019-01-17 2023-06-20 Regents Of The University Of Minnesota Antibody fragments for detecting cancer and methods of use
US11235032B2 (en) 2019-01-23 2022-02-01 Massachusetts Institute Of Technology Combination immunotherapy dosing regimen for immune checkpoint blockade
US11236157B2 (en) 2019-01-28 2022-02-01 Galderma Holding SA Treatment of skin lesions and pruritus in prurigo nodularis patients
GB201901305D0 (en) 2019-01-30 2019-03-20 Immunocore Ltd Specific binding molecules
KR20210136014A (ko) 2019-02-12 2021-11-16 암브룩스, 인코포레이티드 항체-tlr 작용제 콘쥬게이트를 함유하는 조성물, 방법 및 이의 용도
WO2020191305A2 (en) 2019-03-20 2020-09-24 Massachusetts Institute Of Technology Uses of amphiphiles in immune cell therapy and compositions therefor
WO2020198136A1 (en) 2019-03-22 2020-10-01 New York Medical College Use of rifaximin on circulating aged neutrophils in sickle cell disease
JPWO2020202839A1 (forum.php) 2019-03-29 2020-10-08
KR20220019670A (ko) 2019-04-17 2022-02-17 고쿠리츠다이가쿠호진 히로시마다이가쿠 Il-6 저해제 및 ccr2 저해제를 조합하여 투여하는 것을 특징으로 하는 비뇨기암의 치료제
JP7455457B2 (ja) 2019-05-10 2024-03-26 タレンゲン インターナショナル リミテッド 筋萎縮性側索硬化症を治療するための方法と薬剤
JPWO2020241816A1 (forum.php) 2019-05-31 2020-12-03
AU2020288499A1 (en) 2019-06-05 2022-01-27 Chugai Seiyaku Kabushiki Kaisha Antibody cleavage site-binding molecule
CN114126649A (zh) 2019-06-10 2022-03-01 中外制药株式会社 用于和细胞因子抑制剂组合使用的抗t细胞抗原结合分子
MX2021014644A (es) 2019-06-13 2022-04-06 Amgen Inc Control de perfusion basado en biomasa automatizado en la fabricacion de productos biologicos.
JP2022538974A (ja) 2019-06-26 2022-09-07 マサチューセッツ インスチテュート オブ テクノロジー 免疫調節融合タンパク質－金属水酸化物錯体およびその方法
KR20220029744A (ko) 2019-07-07 2022-03-08 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규 방법
KR20220032065A (ko) 2019-07-08 2022-03-15 암젠 인크 다중특이성 트랜스타이레틴 면역글로불린 융합
PH12021552960A1 (en) 2019-07-10 2022-07-25 Chugai Pharmaceutical Co Ltd Claudin-6 binding molecules and uses thereof
AU2020323901A1 (en) 2019-07-26 2022-02-24 Amgen Inc. Anti-IL13 antigen binding proteins
GB201910899D0 (en) 2019-07-31 2019-09-11 Scancell Ltd Binding members
GB201910900D0 (en) 2019-07-31 2019-09-11 Scancell Ltd Modified fc-regions to enhance functional affinity of antibodies and antigen binding fragments thereof
AU2020328038A1 (en) 2019-08-13 2022-03-31 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
GB201912657D0 (en) 2019-09-03 2019-10-16 Scancell Ltd Binding members
GB201912882D0 (en) 2019-09-06 2019-10-23 Scancell Ltd Ssea-4 binding members
KR20220062500A (ko) 2019-09-16 2022-05-17 서피스 온콜로지, 인크. 항-cd39 항체 조성물 및 방법
EP4034559A1 (en) 2019-09-25 2022-08-03 Surface Oncology, Inc. Anti-il-27 antibodies and uses thereof
TWI745114B (zh) 2019-10-11 2021-11-01 日商中外製藥股份有限公司 用於後天性血友病a之預防及/或治療之醫藥組成物、及包含該醫藥組成物之製品
US20220378817A1 (en) 2019-10-23 2022-12-01 Checkmate Pharmaceuticals, Inc. Synthetic rig-i-like receptor agonists
US11459389B2 (en) 2019-10-24 2022-10-04 Massachusetts Institute Of Technology Monoclonal antibodies that bind human CD161
CA3158893A1 (en) 2019-10-24 2021-04-29 Minotaur Therapeutics, Inc. Chimeric cytokine modified antibodies and methods of use thereof
CA3156683A1 (en) 2019-11-13 2021-05-20 Amgen Inc. METHOD FOR REDUCING AGGREGATE FORMATION IN DOWNSTREAM PROCESSING OF BI-SPECIFIC ANTIGEN-BINDING MOLECULES
BR112022008195A2 (pt) 2019-11-19 2022-07-12 Modag Gmbh Compostos para diagnóstico, tratamento e prevenção de doenças associadas com a agregação de alfa-sinucleína
JP7261942B2 (ja) 2019-12-11 2023-04-20 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
WO2021127262A1 (en) 2019-12-17 2021-06-24 Amgen Inc. Dual interleukin-2 /tnf receptor agonist for use in therapy
EP3838912A1 (en) 2019-12-20 2021-06-23 Herantis Pharma Oyj Retro-inverso peptides
EP3838345A1 (en) 2019-12-20 2021-06-23 Herantis Pharma Oyj Macrocyclic peptides
AU2021205877B2 (en) 2020-01-06 2024-06-20 Vaccinex, Inc. Anti-CCR8 antibodies and uses thereof
CN115666621A (zh) 2020-01-13 2023-01-31 度勒科特公司 具有减少的杂质的持续释放药物递送系统及相关方法
JP7641025B2 (ja) 2020-01-17 2025-03-06 タレンゲン インターナショナル リミテッド 神経損傷及び関連障害を治療するための方法
KR20220137950A (ko) 2020-02-06 2022-10-12 탈렌젠 인터내셔널 리미티드 다발성 경화증의 예방 및 치료 방법 및 약물
WO2021160092A1 (zh) 2020-02-11 2021-08-19 泰伦基国际有限公司 一种治疗病毒性肺炎的方法和药物
JP7616698B2 (ja) 2020-02-26 2025-01-17 タレンゲン インターナショナル リミテッド 血圧異常症を予防及び治療する方法並びに薬剤
WO2021173889A1 (en) 2020-02-26 2021-09-02 Ambrx, Inc. Uses of anti-cd3 antibody folate bioconjugates
EP4117732A1 (en) 2020-03-11 2023-01-18 Ambrx, Inc. Interleukin-2 polypeptide conjugates and methods of use thereof
KR20220155338A (ko) 2020-03-19 2022-11-22 암젠 인크 뮤신 17에 대한 항체 및 이의 용도
TW202143999A (zh) 2020-03-24 2021-12-01 大陸商深圳瑞健生命科學研究院有限公司 一種促進錯誤摺疊蛋白及其聚集物降解的方法和藥物
KR20220158036A (ko) 2020-03-24 2022-11-29 탈렌젠 인터내셔널 리미티드 파킨슨병의 치료 방법 및 약물
WO2021190558A1 (zh) 2020-03-24 2021-09-30 泰伦基国际有限公司 一种治疗阿尔茨海默病的方法和药物
CA3176941A1 (en) 2020-03-24 2021-09-30 Talengen International Limited Method and medicine for treating huntington's disease
JP2023106635A (ja) 2020-04-17 2023-08-02 中外製薬株式会社 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
US20210340524A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
WO2021221782A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Chimeric antigen receptor-targeting ligands and uses thereof
KR20230005298A (ko) 2020-05-11 2023-01-09 탈렌젠 인터내셔널 리미티드 척수성 근위축증의 치료 방법 및 약물
US20230235036A1 (en) 2020-06-05 2023-07-27 The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glads Acvr1 (alk2) receptor inhibition to treat neurological diseases
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
KR102594943B1 (ko) 2020-06-19 2023-10-27 추가이 세이야쿠 가부시키가이샤 혈관신생 저해제와 조합하여 사용하기 위한 항t세포 항원 결합 분자
WO2022006153A1 (en) 2020-06-29 2022-01-06 Resolve Therapeutics, Llc Treatment of sjogren's syndrome with nuclease fusion proteins
WO2022023292A2 (en) 2020-07-31 2022-02-03 Friedrich-Alexander-Universität Erlangen-Nürnberg Corona virus spike protein-targeting antibodies and use thereof
TW202220677A (zh) 2020-07-31 2022-06-01 日商中外製藥股份有限公司 含有表現嵌合受體之細胞的醫藥組成物
AU2021327396A1 (en) 2020-08-20 2023-03-23 Ambrx, Inc. Antibody-TLR agonist conjugates, methods and uses thereof
JP2023539642A (ja) 2020-08-26 2023-09-15 スキャンセル リミテッド ヒトＩｇＧ１の改変ＦＣ領域 及び少なくとも１つの異種抗原を含むポリペプチドをコードする核酸
US20230382978A1 (en) 2020-10-15 2023-11-30 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
WO2022087274A1 (en) 2020-10-21 2022-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies that neutralize type-i interferon (ifn) activity
TW202233680A (zh) 2020-11-06 2022-09-01 德商安美基研究（慕尼黑）公司 具有增加的選擇性之多靶向性雙特異性抗原結合分子
EP4248954A4 (en) 2020-11-17 2024-06-26 Talengen International Limited METHODS AND DRUGS TO INCREASE BDNF LEVELS
JP7682567B2 (ja) 2020-11-17 2025-05-26 泰▲倫▼基国▲際▼有限公司 Ｎｇｆレベルを増加させる方法及び薬剤
US20240228593A9 (en) 2021-02-19 2024-07-11 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services SINGLE DOMAIN ANTIBODIES THAT NEUTRALIZE SARS-CoV-2
AU2022232856A1 (en) 2021-03-12 2023-10-26 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for treatment or prevention of myasthenia gravis
WO2022212899A1 (en) 2021-04-03 2022-10-06 Ambrx, Inc. Anti-her2 antibody-drug conjugates and uses thereof
WO2022232321A1 (en) 2021-04-28 2022-11-03 Minotaur Therapeutics, Inc. Humanized chimeric bovine antibodies and methods of use
AU2022269312A1 (en) 2021-05-06 2023-10-19 Amgen Research (Munich) Gmbh Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
CA3215856A1 (en) 2021-05-07 2022-11-10 Alison O'neill Anti-il-27 antibodies and uses thereof
EP4337243A1 (en) 2021-05-14 2024-03-20 Claris Biotherapeutics, Inc. Compositions of growth factor for the treatment of eye disease
CA3230815A1 (en) 2021-09-03 2023-03-09 University Of Bern Compositions and methods for treating long ot syndrome
WO2023053282A1 (ja) 2021-09-29 2023-04-06 中外製薬株式会社 がんの治療に用いるための細胞傷害誘導治療剤
MX2024005397A (es) 2021-11-03 2024-05-23 Affimed Gmbh Agentes de union a cd16a biespecificos.
KR20240099382A (ko) 2021-11-03 2024-06-28 아피메트 게엠베하 이중특이적 cd16a 결합제
KR102707065B1 (ko) 2022-03-08 2024-09-19 동국제약 주식회사 코아세르베이션법을 이용하여 현탁성이 개선된 미립구의 제조방법
EP4511013A1 (en) 2022-04-19 2025-02-26 Philera New Zealand Ltd. Treatment of brain copper disorders
IL316597A (en) 2022-05-12 2024-12-01 Amgen Res Munich Gmbh Multi-chain, multi-purpose, bispecific antigen-binding compounds with enhanced sensitivity
US20250195510A1 (en) 2022-05-18 2025-06-19 Intra-Cellular Therapies, Inc. Novel methods
WO2023230128A1 (en) 2022-05-25 2023-11-30 Surface Oncology, Inc. Use of anti-il-27 antibodies
WO2023230116A1 (en) 2022-05-25 2023-11-30 Surface Oncology, Inc. Use of anti-il-27 antibodies
EP4541373A1 (en) 2022-06-16 2025-04-23 Osaka University Novel inflammatory disease treatment agent and screening method for same
AR130384A1 (es) 2022-09-02 2024-12-04 Univ Of Bern Composiciones y métodos para tratar el síndrome de qt largo
US20240141050A1 (en) 2022-09-02 2024-05-02 Galderma Holding S.A. Treatments for prurigo nodularis
AU2023343470A1 (en) 2022-09-14 2025-02-06 Amgen Inc. Bispecific molecule stabilizing composition
WO2024076995A1 (en) 2022-10-03 2024-04-11 Insigna Inc. Compositions for non-surgical prevention of boar taint and aggressive behavior
CN120322559A (zh) 2022-10-18 2025-07-15 株式会社Nb健康研究所 抗体、核酸、细胞和药物
CN120152733A (zh) 2022-11-04 2025-06-13 泰伦基国际有限公司 一种促进泛素蛋白酶体系统和自噬溶酶体系统对病理性蛋白清除的方法和药物
CN120112307A (zh) 2022-11-04 2025-06-06 泰伦基国际有限公司 一种促进病理性tdp-43蛋白降解的方法和药物
WO2024121796A1 (en) 2022-12-07 2024-06-13 Fondazione Matilde Tettamanti E Menotti De Marchi Onlus Methods for generating genetically modified cytokine induced killer (cik) cells
CN115804830B (zh) * 2022-12-16 2024-08-20 浙江圣兆药物科技股份有限公司 一种缩短迟滞期的戈舍瑞林缓释植入剂
KR20250123225A (ko) 2022-12-30 2025-08-14 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
WO2024173901A1 (en) 2023-02-17 2024-08-22 Intra-Cellular Therapies, Inc. Lumateperone and derivatives thereof for modulating the nervous system
WO2025006676A2 (en) 2023-06-27 2025-01-02 Firecyte Therapeutics, Inc. Insulin-like growth factor binding protein like 1 (igfbpl1) compositions and methods of use thereof
WO2025111568A1 (en) 2023-11-22 2025-05-30 Intra-Cellular Therapies, Inc. Lumateperone and analogues, as 5-ht2a or 5-ht2a/d2 receptor modulators, for use in the treatment of psychiatric disorders caused by viral, bacterial, or autoimmune encephalitis, and of psychiatric symptoms thereof
WO2025147696A1 (en) 2024-01-05 2025-07-10 Resolve Therapeutics, Llc Treatment of symptoms associated with sars-cov viral infection or a prior sars-cov viral infection with nuclease agents
WO2025155602A1 (en) 2024-01-16 2025-07-24 Genentech, Inc. Method of treating hemophilia a

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3887699A (en) * 1969-03-24 1975-06-03 Seymour Yolles Biodegradable polymeric article for dispensing drugs
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3839297A (en) * 1971-11-22 1974-10-01 Ethicon Inc Use of stannous octoate catalyst in the manufacture of l(-)lactide-glycolide copolymer sutures
JPS5324423B2 (forum.php) * 1972-04-29 1978-07-20
JPS5017525A (forum.php) * 1973-06-14 1975-02-24
JPS5035158A (forum.php) * 1973-07-24 1975-04-03
JPS5749532B2 (forum.php) * 1974-03-19 1982-10-22
JPS5726506B2 (forum.php) * 1974-03-08 1982-06-04
JPS5314072B2 (forum.php) * 1973-09-29 1978-05-15
US3976071A (en) * 1974-01-07 1976-08-24 Dynatech Corporation Methods of improving control of release rates and products useful in same
NZ181036A (en) * 1975-06-12 1978-12-18 A Schally Luteinising hormone releasing hormone analogues and intermediates therefor
US4010196A (en) * 1975-06-25 1977-03-01 American Home Products Corporation Linear polyester salts
US4011312A (en) * 1975-06-25 1977-03-08 American Home Products Corporation Prolonged release drug form for the treatment of bovine mastitis
CA1123984A (en) * 1977-11-16 1982-05-18 Yuzi Okuzumi Block copolymers of lactide and glycolide and surgical prosthesis therefrom
US4234571A (en) * 1979-06-11 1980-11-18 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone
US4333919A (en) * 1979-09-12 1982-06-08 Eli Lilly And Company Growth promotant controlled release formulations and method of treatment
US4331652A (en) * 1979-09-12 1982-05-25 Eli Lilly And Company Controlled release parasitic formulations and method
US4293539A (en) * 1979-09-12 1981-10-06 Eli Lilly And Company Controlled release formulations and method of treatment
US4273920A (en) * 1979-09-12 1981-06-16 Eli Lilly And Company Polymerization process and product
PH17900A (en) * 1979-09-12 1985-01-25 Lilly Co Eli Growth promotant controlled release formulations and method of treatment
PH19942A (en) * 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions

Also Published As

Publication number Publication date
US4767628A (en) 1988-08-30
IE820165L (en) 1982-08-16
DE3273501D1 (en) 1986-11-06
MY101545A (en) 1991-12-17
JPH0686390B2 (ja) 1994-11-02
FI820467L (fi) 1982-08-17
AU2840789A (en) 1989-05-04
AU602623B2 (en) 1990-10-18
FI80594B (fi) 1990-03-30
EP0058481B2 (en) 2003-05-21
JPH0157098B2 (forum.php) 1989-12-04
HU186904B (en) 1985-10-28
AU560829B2 (en) 1987-04-16
CA1169090A (en) 1984-06-12
JPS6264824A (ja) 1987-03-23
HK107890A (en) 1990-12-28
IE52535B1 (en) 1987-12-09
ES509647A0 (es) 1983-08-01
JPH05271051A (ja) 1993-10-19
AU6498886A (en) 1987-02-19
AU582920B2 (en) 1989-04-13
JPH031330B2 (forum.php) 1991-01-10
EP0058481B1 (en) 1986-10-01
ATE22535T1 (de) 1986-10-15
NO162103B (no) 1989-07-31
AU7998682A (en) 1982-08-26
US4767628B1 (forum.php) 1990-07-17
JPH05221871A (ja) 1993-08-31
NO820433L (no) 1982-08-17
US5004602A (en) 1991-04-02
HU199695B (en) 1990-03-28
JPH0774143B2 (ja) 1995-08-09
JPS57150609A (en) 1982-09-17
NO162103C (no) 1992-03-04
NZ199732A (en) 1985-08-30
DK164845B (da) 1992-08-31
PT74434A (en) 1982-03-01
EP0058481A1 (en) 1982-08-25
PT74434B (en) 1983-07-14
DK59182A (da) 1982-08-17
YU31582A (en) 1985-04-30
ES8307845A1 (es) 1983-08-01
GR76791B (forum.php) 1984-09-04
ZA82565B (en) 1982-10-27

Similar Documents

Publication Publication Date Title
US4767628B1 (forum.php)
ES2009346A6 (es) Procedimiento de preparacion de composiciones farmaceuticas que contienen polipeptidos hidroinsolubles.
ATE116540T1 (de) Teilchenzubereitung mit verzögerter wirkstoffabgabe und deren zubereitungsmethode.
LTIP1920A (en) Veterinary composition and process for preparing thereof
DE59305700D1 (de) Verfahren zur Herstellung von festen pharmazeutischen Retardformen
RU93036959A (ru) Свободно растворимый лекарственный препарат с замедленным действием биологически активных веществ, назначенный для приема внутрь, способ его производства
ZA884622B (en) Pharmaceutical compositions in the form of pellets with enzymatically controlled release of the pharmaceutical,substance
AT382076B (de) Verfahren zur herstellung von presslingen mit retardierter wirkstofffreisetzung
HUT47233A (en) Process for producing pharmaceutical comprising phenol derivatives as active ingredient and for producing the active ingredients
EP0230264A3 (en) Pharmaceutical composition for nasal application, process for its preparation and its use
FI881307A7 (fi) Menetelmä sydämeen ja kardiovaskulaariseen järjestelmään vaikuttavien farmaseuttisten koostumusten valmistamiseksi.
DE2962602D1 (en) Process for solubilizing an insoluble drug and an aqueous solution prepared by this process
EP0479177A3 (en) 4- or 5-substituted pyridine-2-carboxylic acids, process for their preparation and their use as medicaments
HUT47124A (en) Process for producing pharmaceutical compositions comprising organic platinum complex as active ingredient and the active ingredients
HUT48096A (en) Insecticides comprising 2-imino-1,3-dithiethane derivatives as active ingredient and process for producing the active ingredients
EP0246861A3 (en) Pharmaceutical composition based on crotoxine, process for preparing the active component and the pharmaceutical composition
EP0193164A3 (en) Sustained-release pharmaceutical preparation which comprised 2-nitroxy-methyl-6-chloropyridine, process for its preparation and use thereof
AR243540A1 (es) Procedimiento quimico para la depolimerizacion controlada de polianiones naturales y productos asi obtenidos, excluidos sus usos farmaceuticos.
Bicknell et al. Mechanism of action of somatostatin: growth-hormone release [45Ca] calcium ion efflux and cyclic nucleotide metabolism of bovine anterior-pituitary slices in the presence of prostaglandin E2 and 1-methyl-3-isobutylxanthine
JPS579711A (en) Preparation of prolonged release type complex
DK45592A (da) Poly(lactid-co-glycolid)polymer omfattende mindst 25 mol% maelkesyreenheder og op til 75 mol% glycosyreenheder samt fremgangsmaade til fremstilling heraf
JPS6442470A (en) Guanidinecarboxylic acid esters, manufacture and medicinal composition
NL7810163A (nl) Arylalkylalkaancarbonzuren, geneesmiddel met als werk- zaam bestanddeel alkaancarbonzuur en werkwijze voor de bereiding van de arylalkylalkaancarbonzuren.
EP0479178A3 (en) 4- or 5-substituted pyridine-2-carboxylic acids, process for their preparation and their use as medicaments
HUT47240A (en) Insecticides and acaricides comprising benzoyl-urea derivatives as active ingredient and process for producing the active ingredients